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ABSTRACT
Acute moderate-intensity exercise transiently suppresses appetite via fluctuations
in the appetite-regulatory peptides acylated ghrelin (AG), peptide tyrosine-tyrosine3-36
(PYY3-36), and active glucagon-like peptide-1 (GLP-1). Importantly, these effects do not
lead to compensatory changes in energy intake in normal weight or obese individuals,
highlighting the potential for exercise to induce acute energy deficits. One potential
mechanism for these effects is increased post-exercise plasma concentrations of interleukin
(IL)-6, as IL-6 has demonstrated appetite-inhibitory effects in animal and cell culture
models. Given obesity is characterized by a state of chronic low-grade inflammation and
associated with upregulated IL-6, this study sought to determine whether IL-6 plays a role
in the appetite-inhibitory effects of moderate-intensity continuous exercise in humans by
utilizing an obese human model. Six lean and six obese sedentary males completed one
non-exercise control (CTRL) and one training session (EX: 60 min, 65% V̇O2max). IL-6,
active GLP-1, PYY3-36, AG, and appetite perceptions were measured fasted, pre-, as well
as 30, 90, and 150 min post-exercise. Fasted IL-6 and active GLP-1 were greater (P≤0.031)
in the obese vs lean group but there were no differences (P>0.05) in fasted AG or PYY3-36.
IL-6 tended to increase in both groups post-exercise (P=0.053), however AG decreased in
the lean group only (P<0.001) with no observable effects of exercise on active GLP-1
(P=0.338), PYY3-36 (P=0.130), or overall appetite (P=0.405) in either group. Further, IL6 was found to moderate the effects of AG and PYY 3-36, but not active GLP-1, at certain
time points post-exercise favouring a reduction in overall appetite. In summary, we
observed little difference in the appetite-regulatory and perceptual response to EX between
lean and obese sedentary males and were unable to conclusively establish whether IL-6
mediates the effects of exercise on appetite regulation.
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CHAPTER 1:
LITERATURE REVIEW
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Introduction
The world’s population has continued to increase since the beginning of the 21 st
century and the global prevalence of obesity has followed a similar trend (Popkin and
Gordon-Larsen 2004). For the first time in history, there are more people around the world
who are obese (body mass index [BMI] ≥30 kg·m-2) than those who are underweight (BMI
≤18.5 kg·m-2; Di Cesare et al. 2016). This global obesity pandemic is preventable, and yet
it continues to strain health care resources, as obesity is associated with a number of
comorbidities including: heart disease (Manson et al. 1995; Meigs et al. 1997);
dyslipidemia (Despres and Krauss, 2004); hypertension (Rocchini 2004); type II diabetes
mellitus (Chan et al. 1994; Colditz et al. 1995); non-alcoholic fatty liver disease (Bellentani
et al. 2000); osteoarthritis (Felson et al. 1988); obstetric complications (Jung 1997); cancer
(Lew and Garfinkel 1979; Schapira et al. 1994); gallbladder disease (Rimm et al. 1975;
Stampfer et al. 1992); early onset dementia (Whitmer et al. 2005); and social stigmatization
(Gortmaker et al. 1993). Not surprisingly then, but perhaps most importantly, obesity leads
to a reduced life span (Fontaine et al. 2003). As such, there is an overwhelming need to
understand obesity in order to guide the research being done to develop effective and nonpharmacological treatment strategies.

Energy imbalance in obesity
While seemingly appropriate to reduce obesity to a problem of eating too much and
moving too little, it is a drastic oversimplification of the underlying processes contributing
to the disease. As it stands, human obesity is the resultant consequence of a chronic
positive energy imbalance brought about via the sensitive interplay between a number of
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physiological, psychological, and environmental factors.

Collectively, these factors

influence the homeostatic regulation of energy balance, that is, the dynamic equilibrium
between energy intake (EI) and energy expenditure (EE) that governs the body’s set-point.
Briefly, the set-point theory holds that body mass is maintained within a predetermined
range via negative feedback, where information from the periphery is relayed to the brain
generating signals that alter EI and/or EE so as to maintain homeostasis at this specific setpoint (Harris 1990). Under normal physiological conditions a balance exists between EI
and EE resulting in a stable body mass over time. However, body mass decreases when
EE exceeds EI and body mass increases when EI exceeds EE (Donnelly and Smith 2005;
Tchernof and Despres 2013), with the latter being the case in the development of obesity.
EI incorporates homeostatic (hormonally regulated) and hedonic (behaviorally regulated)
feeding (Blundell 2006) which is largely influenced by societal and cultural trends,
however the resultant increase in body mass with obesity arises from a transition towards
non-homeostatic hedonic feeding (Davis et al. 2010).
Given that the chronic overconsumption of as few as 100 kilocalories (kcal) per day
can result in obesity (Garland et al. 2011), it appears intuitive that the rates of obesity have
risen in Canada with the advent of the current obesogenic environment, where the
availability of highly palatable, energy dense, and nutritionally deficient foods has
increased (Standing Senate Committee on Social Affairs, Science and Technology, 2016).
Further exacerbating this Canadian obesity epidemic is the fact that only 15% of Canadian
adults actually meet the recommended guideline of 150 minutes of moderate-vigorous
physical activity each week as per the Canadian Society for Exercise Physiology guidelines
(CSEP; Tremblay et al. 2011), despite nearly 50% believing they satisfy this
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recommendation (Standing Senate Committee on Social Affairs, Science and Technology,
2016).
Quite simply, EE remains a highly modifiable factor in the battle against obesity
and by simply reducing sedentary behaviours such as sitting, the potential for increasing
EE by engaging in physical activity inevitably increases. Put together, modification of
only one side of the energy balance equation is insufficient for effective and permanent
reductions in body mass.

Therefore, strategies to combat obesity (such as exercise

interventions) should consider the effects on EE as well as EI, with the most effective
strategies being those that would increase metabolism without increasing appetite (Islam
et al. 2017).

Adipose tissue & adipokine dysregulation in obesity
Obesity is characterized by the excessive and ectopic deposition of adipose tissue
(Bray 2004; World Health Organization 2014) leading to pathophysiological changes
including the dysregulated secretion of adipokines (Fain et al. 2004; Trayhurn and Beattie
2001). Classically, there are two types of adipose tissue: brown adipose tissue (BAT)
involved in thermogenesis and white adipose tissue (WAT) involved in lipid storage.
However, it is worth mentioning a third and increasingly studied adipocyte found in WAT
known as the inducible brown-like (or “beige”) adipocyte (Vitali et al. 2012). These beige
adipocytes quite literally brown the WAT they reside in thereby increasing thermogenesis
in a manner similar to that of BAT (Wu et al. 2012). Moreover, the activity of both brown
and beige adipocytes has been associated with resistance to obesity in animal models
(Cederberg et al. 2001; Kopecky et al. 1995; Seale et al. 2011). Traditionally, BAT was
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believed to exist in mammals and human neonates only, however recent work has
demonstrated the existence of this tissue in human adults suggesting nearly all adults
possess significant amounts of BAT (Cypess et al. 2009; Nedergaard et al. 2007; Saito et
al. 2009; Virtanen et al. 2009).
BAT is the main site of β-adrenergic receptor agonist stimulated adaptive
thermogenesis, or the regulated production of heat (Landsberg et al. 1984).

This

norepinephrine induced activation of protein kinase A via the secondary messenger, cyclic
adenosine monophosphate (cAMP), leads to an increase in genetic transcription via
peroxisome proliferator-activated receptor-gamma coactivator-1 alpha (PGC-1α; Lowell
and Spiegelman 2000). This process is important because it increases both coupled and
uncoupled respiration resulting in adaptive thermogenesis and an increase in EE.
Interestingly, multiple BAT imaging studies have shown the mass and activity of the tissue
to be significantly lower in obese vs non-obese adults (Cypess et al. 2009; Virtanen et al.
2009), suggesting that a decrease in EE through the aforementioned pathway could
partially explain the resultant increase in adiposity in these individuals.
Comparatively, WAT accounts for the majority of adipose tissue in humans and is
recognized as an endocrine organ capable of secreting various hormones known as
adipokines (Fain et al. 2004). In turn, these adipokines exert pleiotropic effects on tissues
via paracrine, autocrine, or endocrine signaling actions to promote interorgan crosstalk and
the regulation of various physiological processes (Fantuzzi 2005; Trayhurn and Beattie
2001). While there has been debate as to where in the adipose tissue these adipokines come
from (Bastard et al. 1999; Fain et al. 2004; Yudkin et al. 1999a), there is strong evidence
to suggest that the release of >90% of these adipokines are from the stromal vascular
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fraction of cells in the adipose tissue matrix and not the adipocytes themselves (Fain 2010;
Fain et al. 2004). In obesity the plasma concentrations of many adipokines are altered
(Fain et al. 2004) leading to disruptions in metabolism and a number of comorbid
conditions. Most notably perhaps is the altered concentration of interleukin-6 (IL-6;
Bastard et al. 2002; Bruun et al. 2003; Engeli et al. 2003; Esposito et al. 2003; Ramsay et
al. 2002; Skurk et al. 2002; Yudkin et al. 1999b), however others worth mentioning
include: plasminogen activator inhibitor-1 (PAI-1; Carmichael et al. 2002; Primrose et al.
1992; Skurk et al. 2002; Sylvan et al. 1992); tumor necrosis factor alpha (TNF-α; Katsuki
et al. 1998; Yudkin et al. 1999b) and leptin and adiponectin (Ahima and Flier 2000; Frayn
et al. 2003; Matsubara et al. 2002; Mora and Pessin 2002). It is important to appreciate
the microenvironment present in the obese state given that a number of obesity-related
comorbidities, such as insulin resistance and inflammation are attributed to the
dysregulated secretion of various ‘-kines’.

Proinflammatory adipokines & systemic inflammation
Despite their functional classification as cytokines, IL-6 and TNF-α should be
referred to as adipokines (not adipocytokines) in the instances where these proteins are
synthesized by and secreted from adipose tissue, as this reflects an effort to keep in line
with previous calls for consistent terminology (Trayhurn and Wood 2004). TNF-α is
mainly produced by activated macrophages within adipose tissue as part of the
inflammatory response (Hotamisligil et al. 1993). TNF-α acts on two specific receptors:
glycoprotein (gp)60 and gp80, although its affinity for gp80 which is expressed on immune
cells is much greater (Sarzi-Puttini et al. 2005). TNF-α exerts a number of autocrine effects
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on adipose tissue including the stimulation of lipolysis and apoptosis (Prins et al. 1997;
Ryden et al. 2004) however it has also been shown to inhibit insulin signaling leading to
insulin resistance and diabetes (Hotamisligil et al. 1994; Hotamisligil et al. 1996). Specific
to the inflammatory response, TNF-α promotes the recruitment of macrophages (Kanda et
al. 2006) and the secretion of IL-6 while also inhibiting the release of adiponectin (Wang
and Trayhurn 2006). IL-6 (discussed in detail later) is produced by both adipocytes and
macrophages within adipose tissue, with visceral WAT contributing more to the circulating
plasma concentration than that of subcutaneous WAT (Fain et al. 2004; Fried et al. 1998).
WAT contributes ~30% of the circulating IL-6 when inflammation is absent (MohamedAli et al. 1997), however in the presence of inflammation its production is upregulated and
chronic exposure to IL-6 occurs. IL-6 plays a key role in the immune response as it induces
the production of the acute phase protein C-reactive protein (CRP) by hepatocytes that in
turn activates the classical complement system (Ridker 2016). The classical complement
system is a part of the larger innate immune response and works to defend the host against
pathogens in concert with mast cells and macrophages with the ultimate goal being the
induction of cell lysis, death, and the eventual clearance of the foreign/necrotic cellular
debris via phagocytosis (as reviewed in Mold et al. 1999). Interestingly, IL-6 also mediates
the transition from an acute to chronic inflammatory state (Kaplanski et al. 2003).
In addition to describing the role of adipokines in the inflammatory state underlying
obesity, it is important to consider why obesity is characterized by an inflammatory state
in the first place. The prevailing hypothesis is that the increase in inflammatory proteins
and factors present within the circulation reflect spillover from adipose tissue, which is
itself in an inflammatory state due to a hypoxic environment (Trayhurn and Wood 2004).
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It makes logical sense that with the increased adiposity in obesity there would be an
increased need for vascularization of the tissue, however if the tissue grew too large for the
pre-existing vasculature to maintain normoxia then a relative state of hypoxia and the
subsequent inflammatory response to that distress would ensue. This hypoxia hypothesis
is central to understanding the inflammatory state present in obesity and has been widely
accepted (Fujisaka et al. 2013; Kabon et al. 2004; Trayhurn 2013; Trayhurn and Wood
2004).
While the mechanisms of the inflammatory process in response to an infection have
been thoroughly described (Medzhitov 2008), the mechanisms underlying the process in
obesity have yet to be described to the same extent. What seems to be similar is that the
process is initiated by mast cells and activated macrophages residing within the adipose
tissue (Weisberg et al. 2003), albeit the event preceding this in obesity is the necrosis of
adipocytes due to hypoxia and not some invading pathogen (refer to Figure 1 for an
overview of the inflammatory process specific to obesity).

Specifically, the M1

macrophages displaying a proinflammatory phenotype (Lumeng et al. 2007) produce a
number of proinflammatory factors such as IL-6 and TNF-α to mediate a localized exudate
of the necrotic cellular debris and induce angiogenesis to improve vascularization, all in an
effort to help the tissue adapt to the stressful microenvironment (Medzhitov 2008). Further,
because the stress to the tissue is so great in obesity the resident macrophages recruit
additional M1 macrophages, via the chemokine CC-chemokine ligand 2 (Kanda et al.
2006). Normally, an acute inflammatory state would persist until the pathogen/stress is
removed and the tissue function restored, however in obesity the acute inflammatory
response initially localized to the adipose tissue evolves into a chronic and systemic
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inflammatory response (Kaplanski et al. 2003; Nathan 2008). This systemic inflammation
results in the production of reactive oxygen and reactive nitrogen intermediaries (ROI;
RNI) in the adipose tissue and other cells (Nathan 2008) leading to disrupted cellular
signaling pathways, further activation of M1 macrophages, more inflammation, and in a
feed forward manner more ROI and RNI production (Nathan 2008). Moreover, it is the
spillover of these proinflammatory adipokines from the adipose tissue into the circulation
that results in obese individuals having elevated basal levels of IL-6 (as reviewed in Fain
2010).

Figure 1. General overview of the inflammatory process within adipose tissue (courtesy
of Servier Pharmaceutical’s Medical Art Image Bank). 1. The adipocytes begin to
hypertrophy due to caloric excess. 2. Hypertrophied adipocytes begin producing ROI and
RNI leading to cell damage and the further production of ROI and RNI. 3. Hypoxia sets
in due to the large O2 content relative to pO2. Adipocytes become necrotic and the resident
macrophages initiate the inflammatory response releasing IL-6 and TNF-α. 4.
Macrophages engulf necrotic/apoptotic cellular debris in an attempt to resolve the
inflammatory state of the tissue. Also shown is the concomitant production of ROI and
RNI by other cells (top right) and the spillover of proinflammatory adipokines into the
circulation (bottom right). Note: red triangles are ROI; blue diamonds are RNI; green
hexagons are IL-6; black circles are TNF-α.
17

This chronic and systemic inflammatory state in obesity may therefore represent a
shift in homeostasis towards a new set point in an effort to defend the host. While
inflammation is typically a transient response to restore homeostasis, it is likely that the
systemic inflammatory state in obesity persists due to the repeated generation of reactive
compounds and the propagation of events thereafter, leading the body to target its own
cells as if they were invading pathogens.

This could potentially help explain why

proinflammatory adipokines like TNF-α and IL-6 are chronically upregulated while the
anti-inflammatory adipokine adiponectin is down regulated in obesity and the
inflammatory response never resolves. Moreover, there is sufficient evidence to suggest
that the systemic inflammatory state underlying obesity is particularly distinct in the brain,
specifically in the arcuate nucleus (ARC) region of the hypothalamus (De Souza et al.
2005), the same region that is principally responsible for regulating appetite.

Appetite regulation
Biological overview
Appetite regulation refers to the physiological control of EI and is characterized by
the episodic and tonic signalling of gut-derived peptides that converge on central neuronal
pathways in the ARC (Hussain and Bloom 2013). The ARC is strategically located within
the mediobasal hypothalamus lying above the median eminence (a circumventricular
organ) and on either side of the third ventricle. Due to its location, the ARC can receive
direct input (via receptor-specific binding) from peptides that pass through the fenestrated
capillaries of the median eminence as well as synaptic input from the brainstem (Ueno and
Nakazato 2016). There are two antagonistic neuronal populations in the ARC. The first
class of neurons expresses neuropeptide Y and agouti-related peptide (NPY and AgRP)
18

while the second expresses pro-opiomelanocortin and cocaine and amphetamine regulated
transcript (POMC and CART; Ueno and Nakazato 2016). There are a number of receptors
found on these neurons, including tyrosine-specific receptors (Y1R, Y2R, Y4R, Y5R,
Y6R), melanocortin-specific receptors (MC3R, MC4R), the growth hormone secretagogue
receptor (GHSR) and the leptin receptor (LepR). These receptors have specific agonists
and antagonists and can thus respond to metabolic stimuli to alter EI and EE.
The peptides responsible for binding these receptors are released from the
gastrointestinal tract into the periphery and can be classified as being anorexigenic
(appetite inhibitory) or orexigenic (appetite stimulatory) in nature. To date the only known
orexigenic peptide is ghrelin which stimulates the release of NPY/AgRP (Broberger et al.
1998; Kojima and Kangawa 2005; Patterson et al. 2011), while a number of anorexigenic
peptides exist including: leptin (Friedman and Halaas 1998); cholecystokinin (CCK; Buffa
et al. 1976); pancreatic polypeptide (PP; Chaudhri et al. 2006); peptide tyrosine-tyrosine
(PYY; Adrian et al. 1985); glucagon-like peptide-1 (GLP-1; Herrmann et al. 1995); and
oxyntomodulin (OXM; Le Quellec et al. 1992). All of these anorectic peptides stimulate
the release of POMC/CART or alpha-melanocyte stimulating hormone (α-MSH; a product
of POMC). The orexigenic or anorexigenic classification is attributed to the consequent
effects of the peptides binding their receptor(s). Ultimately, there is a neuronal response
propagated from the ARC to other hypothalamic nuclei involved in the regulation of
appetite (Hussain and Bloom 2013; Ueno and Nakazato 2016).

These additional

hypothalamic regions include the paraventricular nucleus, the dorsomedial nucleus, the
ventromedial nucleus, and the lateral hypothalamus (Bouret et al. 2004; Kalra et al. 1999).
Collectively, the hypothalamus integrates these peripheral and central signals and through
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the higher order processes of the corticolimbic system modulates perceptions of hunger
and satiety that correspond to an induction or suppression of appetite, respectively
(Berthoud 2006).
One important source of neuronal stimulation that spans from the gastrointestinal
tract to the ARC is the vagus nerve. The vagus nerve is composed of many efferent and
afferent sensory fibers with most afferents being distributed along the mucosal and
submucosal layers of the gastrointestinal tract, close to sites of secretion for many peptides.
As such, certain gut-derived peptides can bind receptors on the afferent sensory fibers of
the vagal nerve and stimulate the NTS and hypothalamus (Rinaman 2010), thereby eliciting
the release of neuropeptides indirectly (see Figure 2 for an overview of this process).
Clearly, appetite regulation represents a dauntingly complex set of processes
involving a number of neuroendocrine mechanisms. Appetite regulation represents the
physiological component governing EI, but there are also environmental and social
components that contribute.

Understanding the physiological role appetite plays in

regulating EI and how these processes can be manipulated with exercise is key to
developing effective strategies that lead to healthy weight loss. Keeping in line with this,
the following section will focus specifically and thoroughly on the acute regulation of
appetite via the gut-derived peptides ghrelin, PYY, and GLP-1. These peptides have been
consistently studied as they respond to exercise and changes in their concentrations have
also been shown to alter overall appetite and subsequent EI. While other peptides may
play a role, there is not enough literature to support their inclusion in this project.
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Figure 2.
Overview of the appetite-regulatory process (courtesy of Servier
Pharmaceutical’s Medical Art Image Bank). The anorexigenic peptides (shown in red)
peptide tyrosine-tyrosine (PYY) and glucagon-like peptide-1 (GLP-1) are released from
the small intestine whereas the orexigenic peptide (shown in green) acylated ghrelin (AG)
is released from the stomach. These peptides converge in the arcuate nucleus of the
hypothalamus (ARC) where they exert their appetite stimulatory or inhibitory effects via
the NPY/AgRP and POMC/CART containing neurons, respectively.

Ghrelin - Currently the only known orexigenic appetite-regulating peptide is ghrelin, a 28amino acid peptide principally derived from gastric A cells in times of energetic deficit
(Kojima and Kangawa 2005). The protein product of the ghrelin gene (des-acylated
ghrelin) is biologically inactive and represents the majority of circulating ghrelin.
Following post-translational modification by ghrelin O-acyltransferase (GOAT; which
adds an O-octanoyl group on serine 3) ghrelin becomes acylated and biologically active,
accounting for ~10-20% of total ghrelin (as reviewed in Edwards and Abizaid 2017).
Acylated ghrelin (AG) exerts its appetite-regulatory effects solely via binding to the growth
hormone secretagogue receptor (GHSR) which is expressed on both NPY/AgRP and
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POMC/CART neurons as well as the vagal nerve (Kojima et al. 1999). Importantly, the
addition of the O-octanoyl group permits AG to bind the GHSR except AG is too large to
pass through the blood brain barrier, as such, it is believed AG stimulates GHSRs on vagal
afferents or bypasses the blood brain barrier completely, entering the ARC via
neighbouring circumventricular organs (Edwards and Abizaid 2017).
Peripheral AG concentrations peak immediately prior to feeding and fall
continuously post-prandially reaching a minimum within ~1 h (Tschop et al. 2001a).
Mechanistically, AG binds the GHSR stimulating the release of both neuropeptides NPY
and AgRP. Once released NPY binds the tyrosine receptor subtype-1 (Y1) while AgRP
antagonizes the release of α-MSH and its binding to the anorectic melanocyte-4 receptor
(MC4R). Collectively, this inhibits the POMC/CART neurons by reducing the ratio of
excitatory to inhibitory afferents innervating them, while conversely increasing the ratio of
excitatory afferents innervating the NPY/AgRP neurons and thus their orexigenic effects.
In the post-prandial state when AG levels are decreased the NPY/AgRP neuron activity
declines leading to a reduced inhibition of the POMC/CART neurons and a net increase in
anorexigenic action (Edwards and Abizaid 2017).
In healthy normal weight individuals, AG concentrations decrease in proportion to
the energy and macronutrient content of a meal, with carbohydrate being a primary
stimulus. However, in obesity there are both lower fasting AG concentrations and reduced
suppression following feeding (Callahan et al. 2004; Cummings et al. 2002; Tschop et al.
2001b). The reduced AG concentrations in obesity may appear to represent a homeostatic
attempt to decrease EI however it might actually be an attempt to reduce hyperglycemia.
This is apparent given AG inhibits insulin secretion in obese mice yet obese AG KO mice
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exhibit enhanced glucose-stimulated insulin secretion and improved insulin sensitivity
compared to wild-type controls (Parry et al. 2017). Moreover, while the ghrelin-stimulated
release of NPY and AgRP (described above) is impaired in obese mice, they remain
responsive to icv administration of NPY by increasing food intake, suggesting these
neurons are functional in obesity just insensitive to AG (Briggs et al. 2010). This AG
resistance has been replicated elsewhere (Briggs et al. 2014; Briggs et al. 2013; Lockie et
al. 2015) and confirmed in human cases of obesity (Andrews et al. 2010). Time course
studies have demonstrated that this resistance occurs after just three weeks of exposure to
a high-fat diet (Briggs et al. 2014) but that NPY/AgRP neuron sensitivity to AG can be
restored following weight loss (Briggs et al. 2013). Lastly, such changes in AG levels have
been observed only after the onset of obesity and hyperglycemia suggesting that AG does
not promote obesity via excess EI but rather its decline in concentration during obesity may
be metabolically protective.

PYY – Peptide tyrosine-tyrosine is an anorexigenic appetite-regulating peptide with a 36amino acid sequence and one tyrosine residue at both the N- and C-terminus, giving rise to
its name (“Y” represents the amino acid tyrosine; Adrian et al. 1985). PYY is released
from the enteroendocrine L cells of the small and large intestine with increasing
concentrations distally (Adrian et al. 1985). The secretion pattern of PYY is influenced
directly by caloric load and macronutrient content, with fat being the primary stimulus for
release. Peripheral levels of PYY increase 15 minutes post-prandially, peak within ~1 h
and can remain elevated for up to 6 h (Adrian et al. 1985; Batterham et al. 2003). PYY
can exist in two distinct forms, PYY 1-36, which has an affinity for the tyrosine receptor
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subtypes-1, -4, and -5 (Y1, Y4, Y5; remember NPY also binds Y1), and PYY3-36, which is
a product of post-translational proteolytic cleavage by dipeptidyl peptidase-IV (DPP-IV).
Specifically, DPP-IV cleaves a tyrosine off the N-terminal of PYY1-36 thus generating
PYY3-36 (Mentlein et al. 1993; Walter et al. 1980; Yoshimoto et al. 1980). This is
important because Y1 and Y4 bind to the tyrosine residues on both the C- and N-termini
of PYY1-36 but Y2 only binds the C-terminal. Therefore, PYY3-36 is a selective agonist for
Y2 which is located on the vagal nerve, and the NPY/AgRP and POMC/CART containing
neurons.
PYY3-36 can cross the blood brain barrier to bind Y2, however its half-life is only
~9 minutes (Adrian et al. 1985; Hernandez et al. 1994) so it is likely most of its effects
occur via the vagus nerve. This has been eloquently demonstrated through c-Fos (a marker
of neuronal activation) studies where peripheral administration of PYY 3-36 lit up the area
postrema and NTS, both of which are innervated by the vagus nerve, and furthermore that
sub-diaphragmatic vagotomy leads to a dampening of the effects of PYY 3-36 on appetite
(Koda et al. 2005). Upon binding Y2 in the ARC, PYY3-36 inhibits the release of NPY
while stimulating POMC neurons to release α-MSH resulting in a suppression of appetite
(as reviewed in De Silva and Bloom 2012). Peripherally, PYY3-36 can inhibit gastric
emptying and gastric acid secretion thus prolonging the digestive process (Savage et al.
1987).
Fasting PYY3-36 concentrations are negatively correlated with BMI and the postprandial secretion of this peptide is blunted in obesity (Batterham et al. 2003; le Roux et
al. 2006). It has been hypothesized that these reduced concentrations observed in obesity
are a result of abnormalities in the synthesis and/or release of PYY3-36, but what remains
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unknown is whether this is a cause or consequence of obesity. However, when obese
individuals were given physiologically relevant doses of PYY 3-36 intravenously, they
exhibited a 29.9% reduction in caloric intake at a buffet test meal and a combined 24 h
reduction in EI of 16.5% relative to saline control (Batterham et al. 2003). Similarly, others
have demonstrated that infusing PYY3-36 with OXN (Field et al. 2010) or GLP-1 (Neary et
al. 2005) in obese individuals leads to synergistic effects on decreasing EI compared to the
administration of either peptide alone. These studies demonstrate that obese individuals
remain sensitive to PYY3-36, however in each dosing study the reduction of EI came at the
cost of markedly elevated nausea suggesting the need for more efficacious strategies to
elevate the endogenous concentrations of these peptides.

GLP-1 – Glucagon-like peptide-1 is another anorexigenic peptide, it has a single
polypeptide chain consisting of a 30-amino acid sequence and is secreted within minutes
following a meal (Holst 2006). CHO is the principal stimulus for release of GLP-1 from
the intestinal enteroendocrine L-cells where it is synthesized (Holst 2006; Neary et al.
2005) and thought to be co-secreted with PYY. There are two active forms of GLP-1,
GLP-17-36 and GLP-17-37, however GLP-17-36 represents the majority in the circulation
(Drucker 2006; Orskov et al. 1994). GLP-17-36 has a half-life of ~2 min before it is
degraded to the inactive truncated form GLP-19-36 by DPP-IV (Holst 2006). GLP-17-36
secretion occurs in a biphasic manner with the first peak occurring as CHO is absorbed in
the proximal intestine, and the second peak when nutrients contact receptors on the lumen
of the distal intestine (as reviewed in De Silva and Bloom 2012). There are a number of
GLP-1 receptors throughout the body including areas in the brain, pancreas, heart, kidneys,
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and GI tract, however the function of GLP-1 in most of these locations is currently
unknown (Holst 2006). Importantly, GLP-1 exerts both central and peripheral appetite
regulatory effects (Goke et al. 1995; Holst 2006). In the GI tract, GLP-1 can inhibit
motility (Nauck et al. 1997; Wettergren et al. 1993; Wettergren et al. 1997) and gastric
acid secretion via vagal mechanisms (Wettergren et al. 1994; Wettergren et al. 1997)
leading to delayed gastric emptying and satiation. GLP-1 is also secreted by neurons within
the NTS however despite their close proximity to the ARC c-Fos studies have demonstrated
GLP-1 does not bind receptors there (Abbott et al. 2005; Baggio et al. 2004; Dakin et al.
2004). While contradictory evidence exists (Goke et al. 1995; Tang-Christensen et al.
2001) vagotomy of the brainstem-hypothalamus pathway leads to an attenuation of GLP1’s effects on appetite bolstering the fact this peptide exerts anorexigenic effects via the
brainstem, not the ARC (Abbott et al. 2005).
The total secretion of GLP-1 is reduced in obesity and the post-prandial response
is delayed, collectively resulting in an attenuated anorectic response to feeding (Holst et
al. 1983; Naslund and Hellstrom 1998). Despite this obesity-induced reduction in GLP-1,
administration of exogenous GLP-1 inhibits ad libitum EI in a dose dependent manner
(Verdich et al. 2001) and peripheral administration for 5 days resulted in a 0.55 kg
reduction in body mass (Naslund et al. 2004); collectively suggesting that obese individuals
remain sensitive to the effects of GLP-1 despite a reduced ability to produce and/or secrete
it, similar to that of PYY3-36. In fact, there is evidence to suggest that a GLP-1 feedback
loop regulates the secretion of PYY from enteroendocrine L-cells (Naslund et al. 1999)
and thus it is possible that obesity only dysregulates GLP-1 but by extension, PYY also.
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All of this evidence collectively suggests that obesity results in, or is the result of,
some dysregulation in the synthesis, secretion, and/or sensitivity of appetite regulating
peptides. While multiple studies have used the administration of exogenous peptides to
manipulate the endogenous hormonal milieu and alter appetite, exercise represents a safer,
cheaper, and more natural means of achieving the same end.

Effects of aerobic exercise on appetite regulating peptides in obesity
Exercise protocols of varying durations and intensities have been used as a means
of inducing significant perturbations in EE in both normal weight and obese populations
such that the consequent effects on EI may be studied. Such protocols have included
moderate-intensity continuous training (MICT; 30-60 min at 50-70% V̇O2max); vigorousintensity continuous training (VICT; 30-60 min at 70-85% V̇O2max), high-intensity interval
training (HIIT; alternating work bouts at 85-100% V̇O2max with periods of rest); and sprint
interval training (SIT; 4-6 30 s “all-out” bouts with 240 s rest), although a number of
permutations among these protocols exist in the literature.
The majority of work in the study of exercise and appetite regulation is
observational in nature with only a handful of laboratories exploring the underlying
mechanisms governing these processes. Moreover, many studies are limited by their
inability to attain sufficiently powered designs (Douglas et al. 2016). Most studies employ
crossover designs with 8-12 participants, predominantly males, but even then, very few
studies utilize obese participants making the literature in this population rather sparse. In
order to fully understand the effects of aerobic exercise on appetite regulating peptides in
obesity it is important to first consider how these effects manifest themselves under normal
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physiological conditions (i.e., in non-obese individuals).

Much research has been

undertaken examining the effects of aerobic exercise, specifically MICT, on appetite
regulation (as reviewed in Hazell et al. 2016) in lean males and despite some
inconsistencies (as reviewed in Schubert et al. 2013), it seems generally agreed upon that
exercise induces a suppression of appetite in both a duration and intensity dependent
manner. In line with this, decreases in AG, by as much as 60% relative to rest, with
concomitant increases in PYY and/or GLP-1 have been observed in healthy normal weight
men following MICT as well as SIT protocols (Broom et al. 2009; Deighton et al. 2013;
Douglas et al. 2017; Islam et al. 2017; Shiiya et al. 2011; Ueda et al. 2009a). Importantly,
it has been demonstrated that these transient alterations in appetite regulating peptides
influence appetite perceptions and that normal weight individuals do not compensate for
the exercise-induced increase in EE by increasing EI in the immediate hours post-exercise
(Deighton and Stensel 2014; King et al. 2010a; King et al. 2010b; Schubert et al. 2013).
Similarly, available evidence suggests that exercise does not induce any immediate
compensatory changes in appetite, EI, or appetite peptides in overweight/obese individuals
(Douglas et al. 2017; Holmstrup et al. 2013; Martins et al. 2015; Sim et al. 2014; Unick et
al. 2010).
To date, the only meta-analysis of studies with obese participants found that acute
aerobic exercise transiently decreases AG while increasing total PYY and total GLP-1,
suggesting a net exercise-induced suppression of appetite (Douglas et al. 2016). Although
the effects of exercise on AG were moderate, trivial effects were observed for total PYY
and GLP-1, possibly because only 6 studies were examined for a total pool of 73 obese
participants (Douglas et al. 2016). These data suggest and confirm that the appetite-
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regulatory effects of aerobic exercise are similar between obese and lean individuals
(Schubert et al. 2014), however these results should be interpreted with caution as the
studies examined varied depending on exercise duration, intensity, and the observational
period post-exercise.
In a well-controlled crossover design with 12 healthy obese men and women,
Martins et al. (2015) observed no differences in AG, PYY, GLP-1 or appetite perceptions
between iso-caloric (250 kcal) bouts of moderate- (~70% HRmax) and high-intensity (8 s
“all-out” followed by 12 s rest at a resistance set to elicit 85-90% HRmax) cycling,
suggesting that exercise intensity on its own may not significantly influence appetite in
obese individuals. However, increasing the exercise duration has demonstrated significant
increases in PYY and GLP-1 both in normal weight and obese men following 60 min of
cycling at 50% V̇O2max (Ueda et al. 2009b). In this study, the exercise-induced suppression
of appetite was greater in the obese group compared to the normal weight age-matched
control group despite there being no group differences in concentrations of PYY and GLP1. Recently, Stensel’s group conducted a large investigation (n=47) comparing the effects
of 60 min treadmill running at 60% V̇O2max on appetite and EI between lean and
overweight/obese men and women (Douglas et al. 2017). They found that total PYY
increased with exercise and to a larger degree in lean compared to overweight/obese
participants, yet the exercise-induced increase in total GLP-1 was greater in the
overweight/obese group. There were no significant group differences for AG and despite
appetite being lower during exercise relative to control there were no group differences
(Douglas et al. 2017). This well powered study effectively demonstrates that there are
indeed no compensatory changes in appetite in either lean or overweight/obese participants
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following exercise. This is important as it bolsters the notion that exercise can be used as
a means of inducing an acute negative energy status without leading to compensatory
eating (Douglas et al. 2017). In fact, more than a half century ago it was documented (King
et al. 1997; Mayer et al. 1956), and later described (Catenacci and Wyatt 2007), that with
increased levels of physical activity there is a tighter coupling of EI with EE. Despite all
this, more research is warranted to establish the mechanistic basis for these observations in
lean and overweight/obese individuals.
To date a number of mechanisms have been proposed to explain how acute aerobic
exercise alters the various appetite regulating peptides, including: changes in blood flow
redistribution, gastrointestinal motility, sympathetic nervous system activity, cytokine
release, and lactate production (Hazell et al. 2016). There is also mounting evidence to
suggest that the appetite-inhibitory effects of aerobic exercise can occur in an intensity and
duration dependent manner, with a greater suppression of appetite occurring with
increasing intensities of exercise (Alkahtani et al. 2014; Broom et al. 2017; Islam et al.
2017). Recently, our laboratory linked two of the aforementioned mechanisms, lactate
production and IL-6 release, to the suppression of appetite observed in normal weight men
following MICT (30 min at 65% V̇O2max), VICT (30 min at 85% V̇O2max) and SIT (4 x
30:240 s; Islam et al. 2017). Importantly, the exercise-induced suppression of appetite led
to significant reductions in EI the next day further supporting the role acute aerobic
exercise can play in regulating appetite and ultimately EI. This follows from previous work
demonstrating that 30 min of very-high-intensity intermittent exercise (cycling at 170%
V̇O2peak for 15 s followed by 60 s at 30%) leads to a greater suppression of EI in overweight
men compared to MICT (60% V̇O2peak) and high-intensity-intermittent exercise (60 s at
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100% V̇O2peak followed by 240 s at 50%), despite no difference in ratings of perceived
appetite between trials (Sim et al. 2014). While aerobic exercise of differing intensities
clearly has effects on appetite and appetite regulatory peptides in obesity, no previous work
has established the mechanism responsible for such observations.

Interleukin-6 in obesity
Biological overview
IL-6 is a glycosylated protein existing in multiple isoforms with a molecular weight
of 21-28 kiloDaltons (kDa), depending on the form (Scheller et al. 2011). IL-6 exhibits
three distinct binding sites, one for contacting the IL-6 α-receptor (IL-6R) and two for
contacting specific domains on the membrane-bound β-receptor gp130, all three of which
are located on the membrane of target cells (Scheller et al. 2011). On target cells IL-6 will
bind to the membrane-bound IL-6R (mbIL-6R) and then together this complex will bind to
two molecules of gp130 resulting in IL-6 signal transduction and the subsequent activation
of the Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway
(Mihara et al. 2012; Rawlings et al. 2004; Wolf et al. 2014). Additionally, IL-6 signaling
can be transduced via the mitogen-activated protein kinase (MAPK)- and phosphatidylinositol-3-kinase (PI3K)-pathways (Scheller et al. 2011; Wolf et al. 2014). Due to its
inability to signal at the intracellular level the mbIL-6R is co-localized with gp130, which
is ubiquitously expressed in every human tissue and cell type (Scheller et al. 2011; Wolf
et al. 2014). Furthermore, mbIL-6R expression is tightly regulated with only certain cell
types actually expressing the receptor. In most cases, the existence of a soluble form of
the IL-6R (sIL-6R) activates cells that express gp130 but do not express the mbIL-6R,
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leading to IL-6 signaling. As such, two distinct types of IL-6 signaling exist: classic- and
trans-signaling with the former being associated with anti-inflammatory and the latter proinflammatory effects (Scheller et al. 2011; Wolf et al. 2014). Activation of cells expressing
the mbIL-6R with IL-6 represents classic signaling while activation of cells expressing the
gp130 receptor (but not the mbIL-6R) via the IL-6/sIL-6R complex represents transsignaling.

Role in exercise
At rest, healthy individuals typically exhibit IL-6 concentrations of ~1 pg·mL-1
(Bruunsgaard et al. 1997) whereas chronically elevated IL-6 levels (≤10 pg·mL-1) are
observed in obese individuals at rest (Bastard et al. 2000). Exponential increases in IL-6
(up to 100x resting levels) can occur in a manner directly proportional to the intensity,
duration, and magnitude of muscle mass recruited during exercise (Ostrowski et al. 1998;
Pedersen and Fischer 2007; Steensberg et al. 2000; Trayhurn and Wood 2004). Initially,
IL-6 release was thought to be a result of muscle damage during exercise, however multiple
studies (as reviewed in Fischer 2006) have found that exercises involving eccentric muscle
contractions do not lead to greater increases in plasma IL-6 levels compared to those
involving concentric contractions, effectively demonstrating that the muscle damage
hypothesis was incorrect. It is now generally accepted that IL-6 is released from skeletal
muscle in a contraction dependent manner (Fischer et al. 2004), which is why exercise
modalities that recruit the largest muscle groups (i.e., running and cycling) elicit the
greatest increases in plasma IL-6 concentrations (Fischer 2006). A number of mechanisms
stimulate the release of IL-6 from working skeletal muscle, including: increased oxidative
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stress, low glucose availability, low glycogen content, elevated catecholamines, and
increased intra-cellular calcium build-up (Bergstedt et al. 1993; Cavaliere et al. 2001;
Febbraio et al. 2002).
Reductions in muscle glycogen content following prolonged exercise (i.e., ≥60
min) lead to the transcriptional upregulation and production of IL-6 from skeletal muscle;
this circulating IL-6 then stimulates hepatic glycogenolysis and gluconeogenesis leading
to increases in blood glucose (as reviewed in Hennigar et al. 2017). Concomitantly,
prolonged exercise can stimulate adipose tissue derived IL-6 release into the circulation as
well as increases in lipolysis (Hennigar et al. 2017). Ultimately, this increase in circulating
IL-6 with prolonged exercise serves as a means to enhance the availability of blood glucose
and free fatty acids as a fuel source while sparing muscle glycogen (Hennigar et al. 2017).
This is quite evident as supplementation with carbohydrates during exercise decreases
exercise-induced increases in plasma IL-6 (Fischer 2006) whereas pre-exercise glycogen
depletion protocols lead to marked increases in skeletal muscle IL-6 mRNA and plasma
IL-6 concentrations (Chan et al. 2004; Keller et al. 2001), confirming that a lack of
available substrate to fuel the working muscle is a principal stimulus for IL-6 release.
Further reinforcing this point, it is well documented that aerobic exercise training induces
a number of physiological adaptations including increased muscle glycogen content and
enhanced beta-oxidation (Schantz et al. 1983), however such training also leads to
concomitant reductions in IL-6 concentrations both at rest and in response to exercise,
undoubtedly due to the glycogen sparing shift in substrate utilization following training.
Taken together, this helps explain why moderately intense long duration exercise protocols
that recruit a considerable amount of muscle mass, and lead to depleted blood glucose
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concentrations, have consistently demonstrated the greatest increases in plasma IL-6 levels.
Moreover, this helps explain why non-trained recreationally active individuals display a
greater exercise-induced IL-6 response compared to moderately trained individuals or elite
athletes (Fischer 2006).
Moreover, both acute resistance and aerobic exercise sufficiently stimulate
molecular mechanisms responsible for increasing the plasma concentrations of IL-6, the
sIL-6R and sgp130, as well as the intramuscular transcriptional activation of IL-6R mRNA
(Gray et al. 2008; Keller et al. 2005). With regard to chronic resistance training, the
expression of IL-6 within skeletal muscle actually declines despite the ability to perform
at a higher relative workload (Fischer et al. 2004). In addition to this, chronic resistance
training results in increased skeletal IL-6R transcription and translation at rest (Keller et
al. 2005). Given that IL-6R expression is increased yet IL-6 production decreased with
chronic resistance training, this represents the possibility that such training leads to an
improved IL-6 sensitivity.
In specific regard to aerobic exercise, there is a general consensus that manipulating
exercise duration is more effective at inducing the greatest increase in muscle-derived IL6 compared to manipulating intensity (Fischer 2006). In fact, previous studies employing
cycle ergometry protocols of 60 min at a range of intensities from 50-75% V̇O2max have
demonstrated increases in plasma IL-6 concentrations from 2 to 9 - fold relative to baseline
(MacDonald et al. 2003; Nybo et al. 2002; Starkie et al. 2001; Ullum et al. 1994).
Investigating the effects of exercise and CHO ingestion on IL-6 production, Starkie et al.
(2001) had 7 healthy men cycle for 60 min at a workload equal to lactate threshold and
consume a 6.4% CHO beverage (12 mL·kg-1) during exercise. These authors found that
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CHO ingestion during exercise did not attenuate the increase in skeletal muscle IL-6
mRNA production, as there was a 21-fold increase from baseline. However there was a
blunted increase in plasma IL-6 compared to the non-CHO trial which elicited a 5-fold
increase in plasma IL-6 levels (Starkie et al. 2001). Similar results have been reported
elsewhere (Fischer et al. 2004) and seem logical as CHO supplementation during exercise
would maintain normoglycemia thus decreasing the need for endogenous glucose
production via IL-6 stimulated hepatic glycogenolysis.
While the aforementioned studies employed healthy normal weight male
participants, there is also literature to suggest that healthy obese men can sustain such
efforts. In fact, recent studies with healthy obese participants have utilized both continuous
walking, running, and cycling protocols at relative intensities of 55-75% V̇O2peak for
durations of 30-120 min with no adverse events reported (Cho and Roh 2016; Christiansen
et al. 2013; Ipavec-Levasseur et al. 2015; Kanaley et al. 2014; Schjerve et al. 2008; Slusher
et al. 2015a; Slusher et al. 2015b). Moreover, the International Association for the Study
of Obesity formally recommended in 2003 that obese individuals attain 45-60 min of
moderately-intense physical activity per day (Saris et al. 2003). As such, it has been
thoroughly demonstrated, and formally suggested, that obese individuals are capable of
exercising at moderate-intensities for long durations.
Given the previous discussion on the nature of IL-6 release with exercise, it would
stand to reason that obese men would also exhibit a pronounced skeletal muscle-derived
IL-6 response following such exercise. Consistent with the observation that obesity leads
to chronic low-grade inflammation and elevated IL-6 at rest, Slusher et al. (2015b) found
that obese participants had greater IL-6 concentrations both at rest and in response to 30

35

min of treadmill running at 75% V̇O2max, compared to normal-weight participants. While
the absolute increase in IL-6 in the obese group was greater in this study, the relative
magnitude of IL-6 released following exercise was similar between both groups (Slusher
et al. 2015b). This is contrary to earlier work demonstrating a greater relative release of
IL-6 from obese compared to lean individuals following 120 min of cycling at 55-60%
V̇O2peak (Christiansen et al. 2013), although it is possible the greater exercise duration in
the latter study accounted for the difference in the magnitude of IL-6 released.

Role in appetite regulation
The fact that the magnitude of IL-6 released is greater with longer duration
protocols is especially important for appetite regulation, as greater concentrations of IL-6
may be needed to induce greater production and secretion of key appetite regulating
peptides. There is ample evidence to suggest IL-6 is involved in the control of appetite,
however whether this occurs via central or peripheral mechanisms remains unclear. In
human studies, very little work has been done to examine the role IL-6 plays as a mediator
of the effects of exercise on appetite regulation, especially in obese individuals. One recent
study conducted in normal weight and overweight children, demonstrated that 30 min (3 x
10 min bouts with 1.5 min rest) of cycling at 70% V̇O2max decreased AG and increased IL6 concentrations 120% with no effects on PYY or GLP-1, and no group differences
(Hunschede et al. 2017). The exercise also decreased perceptions of appetite which
inversely correlated with IL-6 concentrations irrespective of weight status (Hunschede et
al. 2017). This supports the acute MICT-induced suppression of appetite (potentially)
mediated by IL-6, however it is contrary to the literature demonstrating effects of MICT

36

on key appetite regulating peptides.

Moreover, a very well designed study using

recreationally active non-obese male twins, only one of whom exercised, demonstrated that
45 min of running at 65% V̇O2max increased IL-6 concentrations by 2.6-fold, and
significantly reduced post-exercise ad libitum EI compared to the non-exercising twin
(Almada et al. 2013). Furthermore, we have recently demonstrated an intensity-dependent
paradigm between IL-6 and appetite (Islam et al. 2017) where we observed greater appetite
suppression with increasing intensities of exercise (i.e., MICT<VICT<SIT). Importantly,
post-exercise increases in IL-6 correlated with increases in GLP-1 and the appetite
suppressive effects of exercise led to reductions in EI the day following exercise (VICT
and SIT only). Despite methodological differences these human studies strongly suggest
IL-6 is involved in appetite regulation, though none of them included obese participants.
In animal models, the central administration of IL-6 reduces EI in healthy mice
meanwhile IL-6 deficient mice develop late-onset obesity, the effects of which can be
attenuated via IL-6 treatment (Timper et al. 2017; Wallenius et al. 2002). Furthermore,
IL-6 stimulates the production and secretion of GLP-1 leading to enhanced insulin
secretion and glucose tolerance, thus establishing IL-6 as a key mediator between insulin
sensitive tissues and the pancreas (Ellingsgaard et al. 2011). Further supporting this role
of IL-6 is the fact that the administration of an IL-6 antibody capable of blocking IL-6
signaling in these mice abolished the production and secretion of GLP-1 (Ellingsgaard et
al. 2011). Whether the relationship between IL-6 and GLP-1 extends to PYY as well is
not well understood, though considering both GLP-1 and PYY are synthesized from the
enteroendocrine L cells and co-released with one another it seems plausible. In cell culture
work using pancreatic cell lines it has been demonstrated that IL-6 reduces ghrelin mRNA
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transcription and protein translation in a dose and time dependent manner (Chew et al.
2014). Collectively, these animal and cell culture experiments demonstrate that IL-6 can
exert modulatory effects on key appetite regulating peptides in a manner consistent with a
decrease in appetite. However, there is a need for this work to be extended into a human
model of obesity.

Gap in the literature
This work will serve as a direct human extension of previous animal and cell culture
experiments that demonstrated IL-6 exerts appetite-inhibitory effects by dose- and timedependently down regulating ghrelin mRNA expression ex vivo in pancreatic cells, while
also increasing GLP-1 secretion ex vivo from GLUTag cells and in vivo from mouse
enteroendocrine L cells (Chew et al. 2014; Ellingsgaard et al. 2011). To accomplish this,
we chose to use an obese human model given obesity is associated with a chronic state of
low-grade inflammation, characterized by increased IL-6 concentrations at rest (Bastard et
al. 2000; Trayhurn and Wood 2004). Further, by having obese participants complete a
long duration moderate-intensity aerobic exercise protocol (60 min cycling at 65% V̇O2max)
we will be able to further increase their endogenous IL-6 concentrations and study the
consequent effects of IL-6 on appetite-regulating peptides post-exercise relative to a lean
sedentary control group and a non-exercising control session. Furthermore, this study
seeks to establish exercise-induced increases in IL-6 as a physiologically plausible
mechanism of appetite regulation and in doing so move beyond simply describing the
effects of exercise on appetite regulation as is typically the case in the literature.
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Objective
To examine whether a single bout of MICT can induce an increase in circulating
IL-6 concentrations that results in a reduced post-exercise appetite as per alterations in
appetite-regulatory peptides and psychological perceptions of appetite.

Hypotheses
i.

The obese group will have lower fasting concentrations of AG, PYY3-36, and active
GLP-1 but greater fasting concentrations of IL-6 compared to the lean group.

ii.

The absolute, but not relative, exercise-induced increase in IL-6 will be greater in the
obese vs lean group.

iii.

There will be a positive association between IL-6 and active GLP-1 following
exercise and this relationship will be stronger in the obese vs lean group.

iv.

Exercise will reduce AG concentrations and increase PYY3-36 and active GLP-1
concentrations relative to the control session and irrespective of group.

39

References
Abbott, C.R., Monteiro, M., Small, C.J., Sajedi, A., Smith, K.L., Parkinson, J.R., . . .
Bloom, S.R. (2005). The inhibitory effects of peripheral administration of peptide
YY(3-36) and glucagon-like peptide-1 on food intake are attenuated by ablation of
the vagal-brainstem-hypothalamic pathway. Brain Res 1044: 127-31.
Adrian, T.E., Ferri, G.L., Bacarese-Hamilton, A.J., Fuessl, H.S., Polak, J.M., and Bloom,
S.R. (1985). Human distribution and release of a putative new gut hormone, peptide
YY. Gastroenterology 89: 1070-7.
Ahima, R.S. and Flier, J.S. (2000). Leptin. Annu Rev Physiol 62: 413-37.
Alkahtani, S.A., Byrne, N.M., Hills, A.P., and King, N.A. (2014). Interval training intensity
affects energy intake compensation in obese men. Int J Sport Nutr Exerc Metab
24: 595-604.
Almada, C., Cataldo, L.R., Smalley, S.V., Diaz, E., Serrano, A., Hodgson, M.I., and Santos,
J.L. (2013). Plasma levels of interleukin-6 and interleukin-18 after an acute
physical exercise: relation with post-exercise energy intake in twins. J Physiol
Biochem 69: 85-95.
Andrews, Z.B., Erion, D.M., Beiler, R., Choi, C.S., Shulman, G.I., and Horvath, T.L.
(2010). Uncoupling protein-2 decreases the lipogenic actions of ghrelin.
Endocrinology 151: 2078-86.
Baggio, L.L., Huang, Q., Brown, T.J., and Drucker, D.J. (2004). Oxyntomodulin and
glucagon-like peptide-1 differentially regulate murine food intake and energy
expenditure. Gastroenterology 127: 546-58.
Bastard, J.P., Jardel, C., Bruckert, E., Blondy, P., Capeau, J., Laville, M., . . . Hainque, B.
(2000). Elevated levels of interleukin 6 are reduced in serum and subcutaneous
adipose tissue of obese women after weight loss. J Clin Endocrinol Metab 85:
3338-42.
Bastard, J.P., Jardel, C., Delattre, J., Hainque, B., Bruckert, E., and Oberlin, F. (1999).
Evidence for a link between adipose tissue interleukin-6 content and serum Creactive protein concentrations in obese subjects. Circulation 99: 2221-2.
Bastard, J.P., Maachi, M., Van Nhieu, J.T., Jardel, C., Bruckert, E., Grimaldi, A., . . .
Hainque, B. (2002). Adipose tissue IL-6 content correlates with resistance to insulin
activation of glucose uptake both in vivo and in vitro. J Clin Endocrinol Metab
87: 2084-9.
Batterham, R.L., Cohen, M.A., Ellis, S.M., Le Roux, C.W., Withers, D.J., Frost, G.S., . . .
Bloom, S.R. (2003). Inhibition of food intake in obese subjects by peptide YY3-36.
N Engl J Med 349: 941-8.

40

Batterham, R.L., Heffron, H., Kapoor, S., Chivers, J.E., Chandarana, K., Herzog, H., . . .
Withers, D.J. (2006). Critical role for peptide YY in protein-mediated satiation and
body-weight regulation. Cell Metab 4: 223-33.
Bellentani, S., Saccoccio, G., Masutti, F., Croce, L.S., Brandi, G., Sasso, F., . . . Tiribelli,
C. (2000). Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann
Intern Med 132: 112-7.
Bergstedt, K., Hu, B.R., and Wieloch, T. (1993). Initiation of protein synthesis and heatshock protein-72 expression in the rat brain following severe insulin-induced
hypoglycemia. Acta Neuropathol 86: 145-53.
Berthoud, H.R. (2006). Homeostatic and non-homeostatic pathways involved in the control
of food intake and energy balance. Obesity (Silver Spring) 14 Suppl 5: 197S-200S.
Blundell, J.E. (2006). Perspective on the central control of appetite. Obesity (Silver
Spring) 14 Suppl 4: 160S-163S.
Bouret, S.G., Draper, S.J., and Simerly, R.B. (2004). Formation of projection pathways
from the arcuate nucleus of the hypothalamus to hypothalamic regions implicated
in the neural control of feeding behavior in mice. J Neurosci 24: 2797-805.
Bray, G.A. (2004). Medical consequences of obesity. J Clin Endocrinol Metab 89: 25839.
Briggs, D.I., Enriori, P.J., Lemus, M.B., Cowley, M.A., and Andrews, Z.B. (2010). Dietinduced obesity causes ghrelin resistance in arcuate NPY/AgRP neurons.
Endocrinology 151: 4745-55.
Briggs, D.I., Lockie, S.H., Benzler, J., Wu, Q., Stark, R., Reichenbach, A., . . . Andrews,
Z.B. (2014). Evidence that diet-induced hyperleptinemia, but not hypothalamic
gliosis, causes ghrelin resistance in NPY/AgRP neurons of male mice.
Endocrinology 155: 2411-22.
Briggs, D.I., Lockie, S.H., Wu, Q., Lemus, M.B., Stark, R., and Andrews, Z.B. (2013).
Calorie-restricted weight loss reverses high-fat diet-induced ghrelin resistance,
which contributes to rebound weight gain in a ghrelin-dependent manner.
Endocrinology 154: 709-17.
Broberger, C., Johansen, J., Johansson, C., Schalling, M., and Hokfelt, T. (1998). The
neuropeptide Y/agouti gene-related protein (AGRP) brain circuitry in normal,
anorectic, and monosodium glutamate-treated mice. Proc Natl Acad Sci U S A 95:
15043-8.
Broom, D.R., Batterham, R.L., King, J.A., and Stensel, D.J. (2009). Influence of resistance
and aerobic exercise on hunger, circulating levels of acylated ghrelin, and peptide
YY in healthy males. Am J Physiol Regul Integr Comp Physiol 296: R29-35.

41

Broom, D.R., Miyashita, M., Wasse, L.K., Pulsford, R., King, J.A., Thackray, A.E., and
Stensel, D.J. (2017). Acute effect of exercise intensity and duration on acylated
ghrelin and hunger in men. J Endocrinol 232: 411-422.
Bruun, J.M., Verdich, C., Toubro, S., Astrup, A., and Richelsen, B. (2003). Association
between measures of insulin sensitivity and circulating levels of interleukin-8,
interleukin-6 and tumor necrosis factor-alpha. Effect of weight loss in obese men.
Eur J Endocrinol 148: 535-42.
Bruunsgaard, H., Galbo, H., Halkjaer-Kristensen, J., Johansen, T.L., MacLean, D.A., and
Pedersen, B.K. (1997). Exercise-induced increase in serum interleukin-6 in humans
is related to muscle damage. J Physiol 499 ( Pt 3): 833-41.
Buffa, R., Solcia, E., and Go, V.L. (1976). Immunohistochemical identification of the
cholecystokinin cell in the intestinal mucosa. Gastroenterology 70: 528-32.
Callahan, H.S., Cummings, D.E., Pepe, M.S., Breen, P.A., Matthys, C.C., and Weigle, D.S.
(2004). Postprandial suppression of plasma ghrelin level is proportional to ingested
caloric load but does not predict intermeal interval in humans. J Clin Endocrinol
Metab 89: 1319-24.
Carmichael, A.R., Tate, G., King, R.F., Sue-Ling, H.M., and Johnston, D. (2002). Effects
of the Magenstrasse and Mill operation for obesity on plasma plasminogen activator
inhibitor type 1, tissue plasminogen activator, fibrinogen and insulin. Pathophysiol
Haemost Thromb 32: 40-3.
Catenacci, V.A. and Wyatt, H.R. (2007). The role of physical activity in producing and
maintaining weight loss. Nat Clin Pract Endocrinol Metab 3: 518-29.
Cavaliere, F., D'Ambrosi, N., Sancesario, G., Bernardi, G., and Volonte, C. (2001).
Hypoglycaemia-induced cell death: features of neuroprotection by the P2 receptor
antagonist basilen blue. Neurochem Int 38: 199-207.
Cederberg, A., Gronning, L.M., Ahren, B., Tasken, K., Carlsson, P., and Enerback, S.
(2001). FOXC2 is a winged helix gene that counteracts obesity,
hypertriglyceridemia, and diet-induced insulin resistance. Cell 106: 563-73.
Chan, J.M., Rimm, E.B., Colditz, G.A., Stampfer, M.J., and Willett, W.C. (1994). Obesity,
fat distribution, and weight gain as risk factors for clinical diabetes in men.
Diabetes Care 17: 961-9.
Chan, M.H., McGee, S.L., Watt, M.J., Hargreaves, M., and Febbraio, M.A. (2004).
Altering dietary nutrient intake that reduces glycogen content leads to
phosphorylation of nuclear p38 MAP kinase in human skeletal muscle: association
with IL-6 gene transcription during contraction. FASEB J 18: 1785-7.
Chaudhri, O., Small, C., and Bloom, S. (2006). Gastrointestinal hormones regulating
appetite. Philos Trans R Soc Lond B Biol Sci 361: 1187-209.
42

Chew, C., Choo, Q., Lim, W., Lao, K., Wong, S., and Chow, X. (2014). IL-6 possible
modulates ghrelin expression through MEK1/p90RSK signaling cascade in
pancreatic cell lines. Cytokine 70: 34.
Cho, S.Y. and Roh, H.T. (2016). Effects of aerobic exercise training on peripheral brainderived neurotrophic factor and eotaxin-1 levels in obese young men. J Phys Ther
Sci 28: 1355-8.
Christiansen, T., Bruun, J.M., Paulsen, S.K., Olholm, J., Overgaard, K., Pedersen, S.B.,
and Richelsen, B. (2013). Acute exercise increases circulating inflammatory
markers in overweight and obese compared with lean subjects. Eur J Appl Physiol
113: 1635-42.
Colditz, G.A., Willett, W.C., Rotnitzky, A., and Manson, J.E. (1995). Weight gain as a risk
factor for clinical diabetes mellitus in women. Ann Intern Med 122: 481-6.
Cummings, D.E., Weigle, D.S., Frayo, R.S., Breen, P.A., Ma, M.K., Dellinger, E.P., and
Purnell, J.Q. (2002). Plasma ghrelin levels after diet-induced weight loss or gastric
bypass surgery. N Engl J Med 346: 1623-30.
Cypess, A.M., Lehman, S., Williams, G., Tal, I., Rodman, D., Goldfine, A.B., . . . Kahn,
C.R. (2009). Identification and importance of brown adipose tissue in adult humans.
N Engl J Med 360: 1509-17.
Dakin, C.L., Small, C.J., Batterham, R.L., Neary, N.M., Cohen, M.A., Patterson, M., . . .
Bloom, S.R. (2004). Peripheral oxyntomodulin reduces food intake and body
weight gain in rats. Endocrinology 145: 2687-95.
Davis, C., Patte, K., Curtis, C., and Reid, C. (2010). Immediate pleasures and future
consequences. A neuropsychological study of binge eating and obesity. Appetite
54: 208-213.
De Silva, A. and Bloom, S.R. (2012). Gut Hormones and Appetite Control: A Focus on
PYY and GLP-1 as Therapeutic Targets in Obesity. Gut Liver 6: 10-20.
De Souza, C.T., Araujo, E.P., Bordin, S., Ashimine, R., Zollner, R.L., Boschero, A.C., . . .
Velloso, L.A. (2005). Consumption of a fat-rich diet activates a proinflammatory
response and induces insulin resistance in the hypothalamus. Endocrinology 146:
4192-9.
Deighton, K., Karra, E., Batterham, R.L., and Stensel, D.J. (2013). Appetite, energy intake,
and PYY3-36 responses to energy-matched continuous exercise and submaximal
high-intensity exercise. Appl Physiol Nutr Metab 38: 947-52.
Deighton, K. and Stensel, D.J. (2014). Creating an acute energy deficit without stimulating
compensatory increases in appetite: is there an optimal exercise protocol? Proc
Nutr Soc 73: 352-8.

43

Despres, J.P. and Krauss, R.M. (2004). Obesity and lipoprotein metabolism. In: Bray, G.A.,
Bouchard, C., and James, W.P. Handbook of obesity: etiology and
pathophysiology. 2nd ed. New York: Marcel Dekker; 845-871.
Di Cesare, M., Bentham, J., Stevens, G.A., Zhou, B., Danaei, G., Lu, Y., . . . NCD, N.R.F.C.
(2016). Trends in adult body-mass index in 200 countries from 1975 to 2014: a
pooled analysis of 1698 population-based measurement studies with 19.2 million
participants. Lancet 387: 1377-1396.
Donnelly, J.E. and Smith, B.K. (2005). Is exercise effective for weight loss with ad libitum
diet? Energy balance, compensation, and gender differences. Exerc Sport Sci Rev
33: 169-74.
Douglas, J.A., Deighton, K., Atkinson, J.M., Sari-Sarraf, V., Stensel, D.J., and Atkinson,
G. (2016). Acute Exercise and Appetite-Regulating Hormones in Overweight and
Obese Individuals: A Meta-Analysis. J Obes 2016: 2643625.
Douglas, J.A., King, J.A., Clayton, D.J., Jackson, A.P., Sargeant, J.A., Thackray, A.E., . .
. Stensel, D.J. (2017). Acute effects of exercise on appetite, ad libitum energy intake
and appetite-regulatory hormones in lean and overweight/obese men and women.
Int J Obes (Lond) 41: 1737-1744.
Drucker, D.J. (2006). The biology of incretin hormones. Cell Metab 3: 153-65.
Edwards, A. and Abizaid, A. (2017). Clarifying the Ghrelin System's Ability to Regulate
Feeding Behaviours Despite Enigmatic Spatial Separation of the GHSR and Its
Endogenous Ligand. Int J Mol Sci 18.
Ellingsgaard, H., Hauselmann, I., Schuler, B., Habib, A.M., Baggio, L.L., Meier, D.T., . .
. Donath, M.Y. (2011). Interleukin-6 enhances insulin secretion by increasing
glucagon-like peptide-1 secretion from L cells and alpha cells. Nat Med 17: 14819.
Engeli, S., Feldpausch, M., Gorzelniak, K., Hartwig, F., Heintze, U., Janke, J., . . . Sharma,
A.M. (2003). Association between adiponectin and mediators of inflammation in
obese women. Diabetes 52: 942-7.
Esposito, K., Pontillo, A., Giugliano, F., Giugliano, G., Marfella, R., Nicoletti, G., and
Giugliano, D. (2003). Association of low interleukin-10 levels with the metabolic
syndrome in obese women. J Clin Endocrinol Metab 88: 1055-8.
Fain, J.N. (2010). Release of inflammatory mediators by human adipose tissue is enhanced
in obesity and primarily by the nonfat cells: a review. Mediators Inflamm 2010:
513948.
Fain, J.N., Madan, A.K., Hiler, M.L., Cheema, P., and Bahouth, S.W. (2004). Comparison
of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes

44

from visceral and subcutaneous abdominal adipose tissues of obese humans.
Endocrinology 145: 2273-82.
Fantuzzi, G. (2005). Adipose tissue, adipokines, and inflammation. J Allergy Clin
Immunol 115: 911-9; quiz 920.
Febbraio, M.A., Steensberg, A., Fischer, C.P., Keller, C., Hiscock, N., and Pedersen, B.K.
(2002). IL-6 activates HSP72 gene expression in human skeletal muscle. Biochem
Biophys Res Commun 296: 1264-6.
Felson, D.T., Anderson, J.J., Naimark, A., Walker, A.M., and Meenan, R.F. (1988).
Obesity and knee osteoarthritis. The Framingham Study. Ann Intern Med 109: 1824.
Field, B.C., Wren, A.M., Peters, V., Baynes, K.C., Martin, N.M., Patterson, M., . . . Bloom,
S.R. (2010). PYY3-36 and oxyntomodulin can be additive in their effect on food
intake in overweight and obese humans. Diabetes 59: 1635-9.
Fischer, C.P. (2006). Interleukin-6 in acute exercise and training: what is the biological
relevance? Exerc Immunol Rev 12: 6-33.
Fischer, C.P., Plomgaard, P., Hansen, A.K., Pilegaard, H., Saltin, B., and Pedersen, B.K.
(2004). Endurance training reduces the contraction-induced interleukin-6 mRNA
expression in human skeletal muscle. Am J Physiol Endocrinol Metab 287:
E1189-94.
Fontaine, K.R., Redden, D.T., Wang, C., Westfall, A.O., and Allison, D.B. (2003). Years
of life lost due to obesity. JAMA 289: 187-93.
Frayn, K.N., Karpe, F., Fielding, B.A., Macdonald, I.A., and Coppack, S.W. (2003).
Integrative physiology of human adipose tissue. International Journal of Obesity
27: 875-888.
Fried, S.K., Bunkin, D.A., and Greenberg, A.S. (1998). Omental and subcutaneous adipose
tissues of obese subjects release interleukin-6: depot difference and regulation by
glucocorticoid. J Clin Endocrinol Metab 83: 847-50.
Friedman, J.M. and Halaas, J.L. (1998). Leptin and the regulation of body weight in
mammals. Nature 395: 763-70.
Fujisaka, S., Usui, I., Ikutani, M., Aminuddin, A., Takikawa, A., Tsuneyama, K., . . . Tobe,
K. (2013). Adipose tissue hypoxia induces inflammatory M1 polarity of
macrophages in an HIF-1alpha-dependent and HIF-1alpha-independent manner in
obese mice. Diabetologia 56: 1403-12.
Garland, T., Jr., Schutz, H., Chappell, M.A., Keeney, B.K., Meek, T.H., Copes, L.E., . . .
Eisenmann, J.C. (2011). The biological control of voluntary exercise, spontaneous

45

physical activity and daily energy expenditure in relation to obesity: human and
rodent perspectives. J Exp Biol 214: 206-29.
Goke, R., Larsen, P.J., Mikkelsen, J.D., and Sheikh, S.P. (1995). Distribution of GLP-1
binding sites in the rat brain: evidence that exendin-4 is a ligand of brain GLP-1
binding sites. Eur J Neurosci 7: 2294-300.
Gortmaker, S.L., Must, A., Perrin, J.M., Sobol, A.M., and Dietz, W.H. (1993). Social and
economic consequences of overweight in adolescence and young adulthood. N
Engl J Med 329: 1008-12.
Gray, S.R., Robinson, M., and Nimmo, M.A. (2008). Response of plasma IL-6 and its
soluble receptors during submaximal exercise to fatigue in sedentary middle-aged
men. Cell Stress Chaperones 13: 247-51.
Harris, R.B. (1990). Role of set-point theory in regulation of body weight. FASEB J 4:
3310-8.
Hazell, T.J., Islam, H., Townsend, L.K., Schmale, M.S., and Copeland, J.L. (2016). Effects
of exercise intensity on plasma concentrations of appetite-regulating hormones:
Potential mechanisms. Appetite 98: 80-8.
Hazell, T.J., Townsend, L.K., Hallworth, J.R., Doan, J., and Copeland, J.L. (2017). Sex
differences in the response of total PYY and GLP-1 to moderate-intensity
continuous and sprint interval cycling exercise. Eur J Appl Physiol 117: 431-440.
Hennigar, S.R., McClung, J.P., and Pasiakos, S.M. (2017). Nutritional interventions and
the IL-6 response to exercise. FASEB J 31: 3719-3728.
Hernandez, E.J., Whitcomb, D.C., Vigna, S.R., and Taylor, I.L. (1994). Saturable binding
of circulating peptide YY in the dorsal vagal complex of rats. Am J Physiol 266:
G511-6.
Herrmann, C., Goke, R., Richter, G., Fehmann, H.C., Arnold, R., and Goke, B. (1995).
Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide
plasma levels in response to nutrients. Digestion 56: 117-26.
Holmstrup, M.E., Fairchild, T.J., Keslacy, S., Weinstock, R.S., and Kanaley, J.A. (2013).
Satiety, but not total PYY, Is increased with continuous and intermittent exercise.
Obesity (Silver Spring) 21: 2014-20.
Holst, J.J. (2006). Glucagon-like peptide-1: from extract to agent. The Claude Bernard
Lecture, 2005. Diabetologia 49: 253-60.
Holst, J.J., Schwartz, T.W., Lovgreen, N.A., Pedersen, O., and Beck-Nielsen, H. (1983).
Diurnal profile of pancreatic polypeptide, pancreatic glucagon, gut glucagon and
insulin in human morbid obesity. Int J Obes 7: 529-38.

46

Hotamisligil, G.S., Budavari, A., Murray, D., and Spiegelman, B.M. (1994). Reduced
tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of
tumor necrosis factor-alpha. J Clin Invest 94: 1543-9.
Hotamisligil, G.S., Peraldi, P., Budavari, A., Ellis, R., White, M.F., and Spiegelman, B.M.
(1996). IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in
TNF-alpha- and obesity-induced insulin resistance. Science 271: 665-8.
Hotamisligil, G.S., Shargill, N.S., and Spiegelman, B.M. (1993). Adipose expression of
tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science
259: 87-91.
Hunschede, S., Kubant, R., Akilen, R., Thomas, S., and Anderson, G.H. (2017). Decreased
Appetite after High-Intensity Exercise Correlates with Increased Plasma
Interleukin-6 in Normal-Weight and Overweight/Obese Boys. Curr Dev Nutr 1:
e000398.
Hussain, S.S. and Bloom, S.R. (2013). The regulation of food intake by the gut-brain axis:
implications for obesity. Int J Obes (Lond) 37: 625-33.
Ipavec-Levasseur, S., Croci, I., Choquette, S., Byrne, N.M., Cowin, G., O'Moore-Sullivan,
T.M., . . . Hickman, I.J. (2015). Effect of 1-h moderate-intensity aerobic exercise
on intramyocellular lipids in obese men before and after a lifestyle intervention.
Appl Physiol Nutr Metab 40: 1262-8.
Islam, H., Townsend, L.K., McKie, G.L., Medeiros, P.J., Gurd, B.J., and Hazell, T.J.
(2017). Potential involvement of lactate and interleukin-6 in the appetite-regulatory
hormonal response to an acute exercise bout. J Appl Physiol (1985) 123: 614-623.
Jung, R.T. (1997). Obesity as a disease. British Medical Bulletin 53: 307-321.
Kabon, B., Nagele, A., Reddy, D., Eagon, C., Fleshman, J.W., Sessler, D.I., and Kurz, A.
(2004). Obesity decreases perioperative tissue oxygenation. Anesthesiology 100:
274-80.
Kalra, S.P., Dube, M.G., Pu, S., Xu, B., Horvath, T.L., and Kalra, P.S. (1999). Interacting
appetite-regulating pathways in the hypothalamic regulation of body weight.
Endocr Rev 20: 68-100.
Kanaley, J.A., Heden, T.D., Liu, Y., Whaley-Connell, A.T., Chockalingam, A.,
Dellsperger, K.C., and Fairchild, T.J. (2014). Short-term aerobic exercise training
increases postprandial pancreatic polypeptide but not peptide YY concentrations in
obese individuals. Int J Obes (Lond) 38: 266-71.
Kanda, H., Tateya, S., Tamori, Y., Kotani, K., Hiasa, K., Kitazawa, R., . . . Kasuga, M.
(2006). MCP-1 contributes to macrophage infiltration into adipose tissue, insulin
resistance, and hepatic steatosis in obesity. J Clin Invest 116: 1494-505.

47

Kaplanski, G., Marin, V., Montero-Julian, F., Mantovani, A., and Farnarier, C. (2003). IL6: a regulator of the transition from neutrophil to monocyte recruitment during
inflammation. Trends Immunol 24: 25-9.
Katsuki, A., Sumida, Y., Murashima, S., Murata, K., Takarada, Y., Ito, K., . . . Yano, Y.
(1998). Serum levels of tumor necrosis factor-alpha are increased in obese patients
with noninsulin-dependent diabetes mellitus. Journal of Clinical Endocrinology
& Metabolism 83: 859-862.
Keller, C., Steensberg, A., Hansen, A.K., Fischer, C.P., Plomgaard, P., and Pedersen, B.K.
(2005). Effect of exercise, training, and glycogen availability on IL-6 receptor
expression in human skeletal muscle. J Appl Physiol (1985) 99: 2075-9.
Keller, C., Steensberg, A., Pilegaard, H., Osada, T., Saltin, B., Pedersen, B.K., and Neufer,
P.D. (2001). Transcriptional activation of the IL-6 gene in human contracting
skeletal muscle: influence of muscle glycogen content. FASEB J 15: 2748-50.
King, J.A., Miyashita, M., Wasse, L.K., and Stensel, D.J. (2010a). Influence of prolonged
treadmill running on appetite, energy intake and circulating concentrations of
acylated ghrelin. Appetite 54: 492-8.
King, J.A., Wasse, L.K., Broom, D.R., and Stensel, D.J. (2010b). Influence of brisk
walking on appetite, energy intake, and plasma acylated ghrelin. Med Sci Sports
Exerc 42: 485-92.
King, N.A., Tremblay, A., and Blundell, J.E. (1997). Effects of exercise on appetite
control: implications for energy balance. Med Sci Sports Exerc 29: 1076-89.
Koda, S., Date, Y., Murakami, N., Shimbara, T., Hanada, T., Toshinai, K., . . . Nakazato,
M. (2005). The role of the vagal nerve in peripheral PYY3-36-induced feeding
reduction in rats. Endocrinology 146: 2369-75.
Kojima, M., Hosoda, H., Date, Y., Nakazato, M., Matsuo, H., and Kangawa, K. (1999).
Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature
402: 656-60.
Kojima, M. and Kangawa, K. (2005). Ghrelin: structure and function. Physiol Rev 85:
495-522.
Kopecky, J., Clarke, G., Enerback, S., Spiegelman, B., and Kozak, L.P. (1995). Expression
of the mitochondrial uncoupling protein gene from the aP2 gene promoter prevents
genetic obesity. J Clin Invest 96: 2914-23.
Landsberg, L., Saville, M.E., and Young, J.B. (1984). Sympathoadrenal system and
regulation of thermogenesis. Am J Physiol 247: E181-9.

48

Le Quellec, A., Kervran, A., Blache, P., Ciurana, A.J., and Bataille, D. (1992).
Oxyntomodulin-like immunoreactivity: diurnal profile of a new potential
enterogastrone. J Clin Endocrinol Metab 74: 1405-9.
le Roux, C.W., Batterham, R.L., Aylwin, S.J., Patterson, M., Borg, C.M., Wynne, K.J., . .
. Bloom, S.R. (2006). Attenuated peptide YY release in obese subjects is associated
with reduced satiety. Endocrinology 147: 3-8.
Lew, E.A. and Garfinkel, L. (1979). Variations in mortality by weight among 750,000 men
and women. J Chronic Dis 32: 563-76.
Lockie, S.H., Dinan, T., Lawrence, A.J., Spencer, S.J., and Andrews, Z.B. (2015). Dietinduced obesity causes ghrelin resistance in reward processing tasks.
Psychoneuroendocrinology 62: 114-20.
Lowell, B.B. and Spiegelman, B.M. (2000). Towards a molecular understanding of
adaptive thermogenesis. Nature 404: 652-60.
Lumeng, C.N., Bodzin, J.L., and Saltiel, A.R. (2007). Obesity induces a phenotypic switch
in adipose tissue macrophage polarization. J Clin Invest 117: 175-84.
MacDonald, C., Wojtaszewski, J.F., Pedersen, B.K., Kiens, B., and Richter, E.A. (2003).
Interleukin-6 release from human skeletal muscle during exercise: relation to
AMPK activity. J Appl Physiol (1985) 95: 2273-7.
Manson, J.E., Willett, W.C., Stampfer, M.J., Colditz, G.A., Hunter, D.J., Hankinson, S.E.,
. . . Speizer, F.E. (1995). Body-Weight and Mortality among Women. New
England Journal of Medicine 333: 677-685.
Martins, C., Stensvold, D., Finlayson, G., Holst, J., Wisloff, U., Kulseng, B., . . . King,
N.A. (2015). Effect of moderate- and high-intensity acute exercise on appetite in
obese individuals. Med Sci Sports Exerc 47: 40-8.
Matsubara, M., Maruoka, S., and Katayose, S. (2002). Inverse relationship between plasma
adiponectin and leptin concentrations in normal-weight and obese women. Eur J
Endocrinol 147: 173-80.
Mayer, J., Roy, P., and Mitra, K.P. (1956). Relation between caloric intake, body weight,
and physical work: studies in an industrial male population in West Bengal. Am J
Clin Nutr 4: 169-75.
Medzhitov, R. (2008). Origin and physiological roles of inflammation. Nature 454: 42835.
Meigs, J.B., DAgostino, R.B., Wilson, P.W.F., Cupples, L.A., Nathan, D.M., and Singer,
D.E. (1997). Risk variable clustering in the insulin resistance syndrome - The
Framingham Offspring Study. Diabetes 46: 1594-1600.

49

Mentlein, R., Dahms, P., Grandt, D., and Kruger, R. (1993). Proteolytic processing of
neuropeptide Y and peptide YY by dipeptidyl peptidase IV. Regul Pept 49: 13344.
Mihara, M., Hashizume, M., Yoshida, H., Suzuki, M., and Shiina, M. (2012). IL-6/IL-6
receptor system and its role in physiological and pathological conditions. Clin Sci
(Lond) 122: 143-59.
Mohamed-Ali, V., Goodrick, S., Rawesh, A., Katz, D.R., Miles, J.M., Yudkin, J.S., . . .
Coppack, S.W. (1997). Subcutaneous adipose tissue releases interleukin-6, but not
tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 82: 4196-200.
Mold, C., Gewurz, H., and Du Clos, T.W. (1999). Regulation of complement activation by
C-reactive protein. Immunopharmacology 42: 23-30.
Mora, S. and Pessin, J.E. (2002). An adipocentric view of signaling and intracellular
trafficking. Diabetes Metab Res Rev 18: 345-56.
Naslund, E., Bogefors, J., Skogar, S., Gryback, P., Jacobsson, H., Holst, J.J., and Hellstrom,
P.M. (1999). GLP-1 slows solid gastric emptying and inhibits insulin, glucagon,
and PYY release in humans. Am J Physiol 277: R910-6.
Naslund, E. and Hellstrom, P.M. (1998). Glucagon-like peptide-1 in the pathogenesis of
obesity. Drug News Perspect 11: 92-7.
Naslund, E., King, N., Mansten, S., Adner, N., Holst, J.J., Gutniak, M., and Hellstrom,
P.M. (2004). Prandial subcutaneous injections of glucagon-like peptide-1 cause
weight loss in obese human subjects. Br J Nutr 91: 439-46.
Nathan, C. (2008). Epidemic inflammation: pondering obesity. Mol Med 14: 485-92.
Nauck, M.A., Niedereichholz, U., Ettler, R., Holst, J.J., Orskov, C., Ritzel, R., and
Schmiegel, W.H. (1997). Glucagon-like peptide 1 inhibition of gastric emptying
outweighs its insulinotropic effects in healthy humans. Am J Physiol 273: E981-8.
Neary, N.M., Small, C.J., Druce, M.R., Park, A.J., Ellis, S.M., Semjonous, N.M., . . .
Bloom, S.R. (2005). Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food
intake additively. Endocrinology 146: 5120-7.
Nedergaard, J., Bengtsson, T., and Cannon, B. (2007). Unexpected evidence for active
brown adipose tissue in adult humans. Am J Physiol Endocrinol Metab 293:
E444-52.
Nybo, L., Nielsen, B., Pedersen, B.K., Moller, K., and Secher, N.H. (2002). Interleukin-6
release from the human brain during prolonged exercise. J Physiol 542: 991-5.

50

Orskov, C., Rabenhoj, L., Wettergren, A., Kofod, H., and Holst, J.J. (1994). Tissue and
plasma concentrations of amidated and glycine-extended glucagon-like peptide I in
humans. Diabetes 43: 535-9.
Ostrowski, K., Rohde, T., Zacho, M., Asp, S., and Pedersen, B.K. (1998). Evidence that
interleukin-6 is produced in human skeletal muscle during prolonged running. J
Physiol 508 ( Pt 3): 949-53.
Parry, S.A., Smith, J.R., Corbett, T.R., Woods, R.M., and Hulston, C.J. (2017). Short-term,
high-fat overfeeding impairs glycaemic control but does not alter gut hormone
responses to a mixed meal tolerance test in healthy, normal-weight individuals. Br
J Nutr 117: 48-55.
Patterson, M., Bloom, S.R., and Gardiner, J.V. (2011). Ghrelin and appetite control in
humans--potential application in the treatment of obesity. Peptides 32: 2290-4.
Pedersen, B.K. and Fischer, C.P. (2007). Physiological roles of muscle-derived interleukin6 in response to exercise. Curr Opin Clin Nutr Metab Care 10: 265-71.
Popkin, B.M. and Gordon-Larsen, P. (2004). The nutrition transition: worldwide obesity
dynamics and their determinants. Int J Obes Relat Metab Disord 28 Suppl 3: S29.
Primrose, J.N., Davies, J.A., Prentice, C.R., Hughes, R., and Johnston, D. (1992).
Reduction in factor VII, fibrinogen and plasminogen activator inhibitor-1 activity
after surgical treatment of morbid obesity. Thromb Haemost 68: 396-9.
Prins, J.B., Niesler, C.U., Winterford, C.M., Bright, N.A., Siddle, K., O'Rahilly, S., . . .
Cameron, D.P. (1997). Tumor necrosis factor-alpha induces apoptosis of human
adipose cells. Diabetes 46: 1939-44.
Ramsay, J.E., Ferrell, W.R., Crawford, L., Wallace, A.M., Greer, I.A., and Sattar, N.
(2002). Maternal obesity is associated with dysregulation of metabolic, vascular,
and inflammatory pathways. J Clin Endocrinol Metab 87: 4231-7.
Rawlings, J.S., Rosler, K.M., and Harrison, D.A. (2004). The JAK/STAT signaling
pathway. J Cell Sci 117: 1281-3.
Ridker, P.M. (2016). From C-Reactive Protein to Interleukin-6 to Interleukin-1: Moving
Upstream To Identify Novel Targets for Atheroprotection. Circ Res 118: 145-56.
Rimm, A.A., Werner, L.H., Yserloo, B.V., and Bernstein, R.A. (1975). Relationship of
ovesity and disease in 73,532 weight-conscious women. Public Health Rep 90:
44-51.
Rinaman, L. (2010). Ascending projections from the caudal visceral nucleus of the solitary
tract to brain regions involved in food intake and energy expenditure. Brain Res
1350: 18-34.
51

Rocchini, A.P. (2004). Obesity and blood pressure regulation. In: Bray, G.A., Bouchard,
C., and James, W.P. Handbook of obesity: etiology and pathophysiology. 2nd ed.
New York: Marcel Dekker; 873-897.
Ryden, M., Arvidsson, E., Blomqvist, L., Perbeck, L., Dicker, A., and Arner, P. (2004).
Targets for TNF-alpha-induced lipolysis in human adipocytes. Biochem Biophys
Res Commun 318: 168-75.
Saito, M., Okamatsu-Ogura, Y., Matsushita, M., Watanabe, K., Yoneshiro, T., NioKobayashi, J., . . . Tsujisaki, M. (2009). High incidence of metabolically active
brown adipose tissue in healthy adult humans: effects of cold exposure and
adiposity. Diabetes 58: 1526-31.
Saris, W.H., Blair, S.N., van Baak, M.A., Eaton, S.B., Davies, P.S., Di Pietro, L., . . . Wyatt,
H. (2003). How much physical activity is enough to prevent unhealthy weight gain?
Outcome of the IASO 1st Stock Conference and consensus statement. Obes Rev 4:
101-14.
Sarzi-Puttini, P., Atzeni, F., Doria, A., Iaccarino, L., and Turiel, M. (2005). Tumor necrosis
factor-alpha, biologic agents and cardiovascular risk. Lupus 14: 780-4.
Savage, A.P., Adrian, T.E., Carolan, G., Chatterjee, V.K., and Bloom, S.R. (1987). Effects
of peptide YY (PYY) on mouth to caecum intestinal transit time and on the rate of
gastric emptying in healthy volunteers. Gut 28: 166-70.
Schantz, P., Henriksson, J., and Jansson, E. (1983). Adaptation of human skeletal muscle
to endurance training of long duration. Clin Physiol 3: 141-51.
Schapira, D.V., Clark, R.A., Wolff, P.A., Jarrett, A.R., Kumar, N.B., and Aziz, N.M.
(1994). Visceral Obesity and Breast-Cancer Risk. Cancer 74: 632-639.
Scheller, J., Chalaris, A., Schmidt-Arras, D., and Rose-John, S. (2011). The pro- and antiinflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta
1813: 878-88.
Schjerve, I.E., Tyldum, G.A., Tjonna, A.E., Stolen, T., Loennechen, J.P., Hansen, H.E., . .
. Wisloff, U. (2008). Both aerobic endurance and strength training programmes
improve cardiovascular health in obese adults. Clin Sci (Lond) 115: 283-93.
Schubert, M.M., Desbrow, B., Sabapathy, S., and Leveritt, M. (2013). Acute exercise and
subsequent energy intake. A meta-analysis. Appetite 63: 92-104.
Schubert, M.M., Sabapathy, S., Leveritt, M., and Desbrow, B. (2014). Acute exercise and
hormones related to appetite regulation: a meta-analysis. Sports Med 44: 387-403.
Seale, P., Conroe, H.M., Estall, J., Kajimura, S., Frontini, A., Ishibashi, J., . . . Spiegelman,
B.M. (2011). Prdm16 determines the thermogenic program of subcutaneous white
adipose tissue in mice. J Clin Invest 121: 96-105.
52

Shiiya, T., Ueno, H., Toshinai, K., Kawagoe, T., Naito, S., Tobina, T., . . . Nakazato, M.
(2011). Significant lowering of plasma ghrelin but not des-acyl ghrelin in response
to acute exercise in men. Endocr J 58: 335-42.
Sim, A.Y., Wallman, K.E., Fairchild, T.J., and Guelfi, K.J. (2014). High-intensity
intermittent exercise attenuates ad-libitum energy intake. Int J Obes (Lond) 38:
417-22.
Skurk, T., van Harmelen, V., Lee, Y.M., Wirth, A., and Hauner, H. (2002). Relationship
between IL-6, leptin and adiponectin and variables of fibrinolysis in overweight
and obese hypertensive patients. Horm Metab Res 34: 659-63.
Slusher, A.L., Mock, J.T., Whitehurst, M., Maharaj, A., and Huang, C.J. (2015a). The
impact of obesity on pentraxin 3 and inflammatory milieu to acute aerobic exercise.
Metabolism 64: 323-9.
Slusher, A.L., Whitehurst, M., Zoeller, R.F., Mock, J.T., Maharaj, M., and Huang, C.J.
(2015b). Attenuated fibroblast growth factor 21 response to acute aerobic exercise
in obese individuals. Nutr Metab Cardiovasc Dis 25: 839-45.
Stampfer, M.J., Maclure, K.M., Colditz, G.A., Manson, J.E., and Willett, W.C. (1992).
Risk of symptomatic gallstones in women with severe obesity. Am J Clin Nutr 55:
652-8.
Starkie, R.L., Arkinstall, M.J., Koukoulas, I., Hawley, J.A., and Febbraio, M.A. (2001).
Carbohydrate ingestion attenuates the increase in plasma interleukin-6, but not
skeletal muscle interleukin-6 mRNA, during exercise in humans. J Physiol 533:
585-91.
Steensberg, A., van Hall, G., Osada, T., Sacchetti, M., Saltin, B., and Klarlund Pedersen,
B. (2000). Production of interleukin-6 in contracting human skeletal muscles can
account for the exercise-induced increase in plasma interleukin-6. J Physiol 529 Pt
1: 237-42.
Sylvan, A., Rutegard, J.N., Janunger, K.G., Sjolund, B., and Nilsson, T.K. (1992). Normal
plasminogen activator inhibitor levels at long-term follow-up after jejuno-ileal
bypass surgery in morbidly obese individuals. Metabolism 41: 1370-2.
Tang-Christensen, M., Vrang, N., and Larsen, P.J. (2001). Glucagon-like peptide
containing pathways in the regulation of feeding behaviour. Int J Obes Relat
Metab Disord 25 Suppl 5: S42-7.
Tchernof, A. and Despres, J.P. (2013). Pathophysiology of human visceral obesity: an
update. Physiol Rev 93: 359-404.
Standing Senate Committee on Social Affairs, Science and Technology. (2016). Obesity
in Canada: A whole-of-society approach for a healthier Canada. Retrieved from
https://sencanada.ca/content/sen/committee/421/soci/rms/01mar16/Report-e.htm
53

Timper, K., Denson, J.L., Steculorum, S.M., Heilinger, C., Engstrom-Ruud, L.,
Wunderlich, C.M., . . . Bruning, J.C. (2017). IL-6 Improves Energy and Glucose
Homeostasis in Obesity via Enhanced Central IL-6 trans-Signaling. Cell Rep 19:
267-280.
Trayhurn, P. (2013). Hypoxia and adipose tissue function and dysfunction in obesity.
Physiol Rev 93: 1-21.
Trayhurn, P. and Beattie, J.H. (2001). Physiological role of adipose tissue: white adipose
tissue as an endocrine and secretory organ. Proc Nutr Soc 60: 329-39.
Trayhurn, P. and Wood, I.S. (2004). Adipokines: inflammation and the pleiotropic role of
white adipose tissue. Br J Nutr 92: 347-55.
Tremblay, M.S., Warburton, D.E., Janssen, I., Paterson, D.H., Latimer, A.E., Rhodes, R.E.,
. . . Duggan, M. (2011). New Canadian physical activity guidelines. Appl Physiol
Nutr Metab 36: 36-46; 47-58.
Tschop, M., Wawarta, R., Riepl, R.L., Friedrich, S., Bidlingmaier, M., Landgraf, R., and
Folwaczny, C. (2001a). Post-prandial decrease of circulating human ghrelin levels.
J Endocrinol Invest 24: RC19-21.
Tschop, M., Weyer, C., Tataranni, P.A., Devanarayan, V., Ravussin, E., and Heiman, M.L.
(2001b). Circulating ghrelin levels are decreased in human obesity. Diabetes 50:
707-9.
Ueda, S.Y., Yoshikawa, T., Katsura, Y., Usui, T., and Fujimoto, S. (2009a). Comparable
effects of moderate intensity exercise on changes in anorectic gut hormone levels
and energy intake to high intensity exercise. J Endocrinol 203: 357-64.
Ueda, S.Y., Yoshikawa, T., Katsura, Y., Usui, T., Nakao, H., and Fujimoto, S. (2009b).
Changes in gut hormone levels and negative energy balance during aerobic exercise
in obese young males. J Endocrinol 201: 151-9.
Ueno, H. and Nakazato, M. (2016). Mechanistic relationship between the vagal afferent
pathway, central nervous system and peripheral organs in appetite regulation. J
Diabetes Investig 7: 812-818.
Ullum, H., Haahr, P.M., Diamant, M., Palmo, J., Halkjaer-Kristensen, J., and Pedersen,
B.K. (1994). Bicycle exercise enhances plasma IL-6 but does not change IL-1
alpha, IL-1 beta, IL-6, or TNF-alpha pre-mRNA in BMNC. J Appl Physiol (1985)
77: 93-7.
Unick, J.L., Otto, A.D., Goodpaster, B.H., Helsel, D.L., Pellegrini, C.A., and Jakicic, J.M.
(2010). Acute effect of walking on energy intake in overweight/obese women.
Appetite 55: 413-9.

54

Verdich, C., Flint, A., Gutzwiller, J.P., Naslund, E., Beglinger, C., Hellstrom, P.M., . . .
Astrup, A. (2001). A meta-analysis of the effect of glucagon-like peptide-1 (7-36)
amide on ad libitum energy intake in humans. J Clin Endocrinol Metab 86: 43829.
Virtanen, K.A., Lidell, M.E., Orava, J., Heglind, M., Westergren, R., Niemi, T., . . . Nuutila,
P. (2009). Functional brown adipose tissue in healthy adults. N Engl J Med 360:
1518-25.
Vitali, A., Murano, I., Zingaretti, M.C., Frontini, A., Ricquier, D., and Cinti, S. (2012). The
adipose organ of obesity-prone C57BL/6J mice is composed of mixed white and
brown adipocytes. J Lipid Res 53: 619-29.
Wallenius, V., Wallenius, K., Ahren, B., Rudling, M., Carlsten, H., Dickson, S.L., . . .
Jansson, J.O. (2002). Interleukin-6-deficient mice develop mature-onset obesity.
Nat Med 8: 75-9.
Walter, R., Simmons, W.H., and Yoshimoto, T. (1980). Proline specific endo- and
exopeptidases. Mol Cell Biochem 30: 111-27.
Wang, B. and Trayhurn, P. (2006). Acute and prolonged effects of TNF-alpha on the
expression and secretion of inflammation-related adipokines by human adipocytes
differentiated in culture. Pflugers Arch 452: 418-27.
Weisberg, S.P., McCann, D., Desai, M., Rosenbaum, M., Leibel, R.L., and Ferrante, A.W.,
Jr. (2003). Obesity is associated with macrophage accumulation in adipose tissue.
J Clin Invest 112: 1796-808.
Wettergren, A., Petersen, H., Orskov, C., Christiansen, J., Sheikh, S.P., and Holst, J.J.
(1994). Glucagon-like peptide-1 7-36 amide and peptide YY from the L-cell of the
ileal mucosa are potent inhibitors of vagally induced gastric acid secretion in man.
Scand J Gastroenterol 29: 501-5.
Wettergren, A., Schjoldager, B., Mortensen, P.E., Myhre, J., Christiansen, J., and Holst,
J.J. (1993). Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and
pancreatic functions in man. Dig Dis Sci 38: 665-73.
Wettergren, A., Wojdemann, M., Meisner, S., Stadil, F., and Holst, J.J. (1997). The
inhibitory effect of glucagon-like peptide-1 (GLP-1) 7-36 amide on gastric acid
secretion in humans depends on an intact vagal innervation. Gut 40: 597-601.
Whitmer, R.A., Gunderson, E.P., Barrett-Connor, E., Quesenberry, C.P., Jr., and Yaffe, K.
(2005). Obesity in middle age and future risk of dementia: a 27 year longitudinal
population based study. BMJ 330: 1360.
Wolf, J., Rose-John, S., and Garbers, C. (2014). Interleukin-6 and its receptors: a highly
regulated and dynamic system. Cytokine 70: 11-20.

55

World Health Organization (2014). Obesity and Overweight - Fact Sheet No. 311.
Geneva: World Health Organization.
Wu, Z., Satterfield, M.C., Bazer, F.W., and Wu, G. (2012). Regulation of brown adipose
tissue development and white fat reduction by L-arginine. Curr Opin Clin Nutr
Metab Care 15: 529-38.
Yoshimoto, T., Walter, R., and Tsuru, D. (1980). Proline-specific endopeptidase from
Flavobacterium. Purification and properties. J Biol Chem 255: 4786-92.
Yudkin, J.S., Coppack, S.W., Bulmer, K., Rawesh, A., and Mohamed-Ali, V. (1999a).
Lack of evidence for secretion of plasminogen activator inhibitor-1 by human
subcutaneous adipose tissue in vivo. Thromb Res 96: 1-9.
Yudkin, J.S., Stehouwer, C.D.A., Emeis, J.J., and Coppack, S.W. (1999b). C-reactive
protein in wealthy subjects: Associations with obesity, insulin resistance, and
endothelial dysfunction - A potential role for cytokines originating from adipose
tissue? Arteriosclerosis Thrombosis and Vascular Biology 19: 972-978.

56

CHAPTER 2:
MANUSCRIPT
EXAMINING THE EFFECTS OF INTERLEUKIN-6 ON APPETITE REGULATORY
PEPTIDES IN LEAN AND OBESE SEDENTARY MALES
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Introduction
The world’s population has continued to increase since the beginning of the 21 st
century and the global prevalence of obesity has followed a similar trend (Popkin and
Gordon-Larsen 2004). For the first time in recorded history, there are more people around
the world who are obese than those who are underweight (body mass index [BMI] ≥30
kg·m-2 vs ≤18.5; Di Cesare et al. 2016). Obesity is a disease resulting from a chronic
energy imbalance and is characterized by the excessive and ectopic deposition of adipose
tissue (Bray 2004; World Health Organization 2014), leading to pathophysiological
changes including systemic low-grade inflammation and an impaired appetite regulation
(De Silva and Bloom 2012; Trayhurn and Wood 2004). Appetite regulation refers
specifically to the physiological control of energy intake (EI) and is characterized by the
episodic and tonic signalling of gut-derived peptides that converge on central neuronal
pathways in the arcuate nucleus (ARC) of the hypothalamus (Hussain and Bloom 2013).
All appetite-regulating peptides can be classified as being anorexigenic (appetite
inhibitory) or orexigenic (appetite stimulatory) in nature depending on the neuronal
receptors to which they bind. To date the only known orexigenic peptide is acylated ghrelin
(AG; Broberger et al. 1998; Kojima and Kangawa 2005; Patterson et al. 2011), which
exists in the des-acylated and biologically inactive form until it undergoes posttranslational modification by ghrelin O-acyltransferase (GOAT), becoming acylated and
thus biologically active (Edwards and Abizaid 2017).

Two of the most notable

anorexigenic peptides include: peptide tyrosine-tyrosine3-36 (PYY3-36) and active glucagonlike peptide-1 (GLP-1), both of which are secreted from the enteroendocrine L cells of the
small and large intestines (Adrian et al. 1985; Batterham et al. 2003; Herrmann et al. 1995).
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The secretion of all of these peptides is strongly influenced by either the absence (AG) or
presence (PYY3-36 and GLP-1) of nutrients in the stomach and intestines, respectively, with
each peptide being extremely sensitive to certain macronutrients (Adrian et al. 1986; Holst
2006; Neary et al. 2005). However, in obesity the synthesis and/or secretion of these
peptides is dysregulated leading to abnormal concentrations and an impaired response to
feeding. Notably, obese individuals have lower fasting concentrations of AG, PYY 3-36,
and active GLP-1 alongside an impaired suppression of AG and a blunted secretion of
PYY3-36 and GLP-1 post-prandially (Batterham et al. 2003; Callahan et al. 2004;
Cummings et al. 2002; English et al. 2002; le Roux et al. 2006; le Roux et al. 2005; Tschop
et al. 2001a; Tschop et al. 2001b). This culminates in an attenuated anorectic response to
feeding (Holst et al. 1983; Naslund et al. 1999) that when sustained over time results in an
obese phenotype. However, what remains unknown is if this dysregulation is the cause, or
a consequence of, obesity.
Regardless, obesity is a preventable disease (Bray 2004; World Health
Organization 2014) which can be treated with regular exercise and dietary modifications.
In fact, acute moderate-intensity (50-75% V̇O2max) aerobic exercise transiently suppresses
appetite via fluctuations in AG, PYY3-36, and active GLP-1 (Hazell et al. 2016; Schubert
et al. 2014). Importantly, these effects occur in both lean and obese individuals (Douglas
et al. 2016; Douglas et al. 2017; Marzullo et al. 2008; Ueda et al. 2009) but do not lead to
compensatory changes in EI highlighting the potential for aerobic exercise to induce acute
energy deficits, which when sustained over time, could lead to substantial weight loss. One
potential mechanism for these effects may be the increased post-exercise plasma
concentrations of interleukin (IL)-6 (Hazell et al. 2016). IL-6 is a proinflammatory
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cytokine that has demonstrated direct appetite-inhibitory effects in animal and cell culture
models (Chew et al. 2014; Ellingsgaard et al. 2011), along with associative reductions in
appetite and EI in healthy humans (Almada et al. 2013; Hunschede et al. 2017; Islam et al.
2017). Given obesity is characterized by a state of low-grade inflammation, resting plasma
IL-6 concentrations in these individuals are chronically upregulated relative to their lean
counterparts (Bastard et al. 2000). Moreover, exponential increases in IL-6 occur in a
manner directly proportional to the duration and magnitude of muscle mass recruited
during exercise (Fischer et al. 2004; Ostrowski et al. 1998; Pedersen and Fischer 2007;
Steensberg et al. 2000), with 2 to 9-fold increases in IL-6 observed following 60 min of
cycling at 50-75% V̇O2max (MacDonald et al. 2003; Nybo et al. 2002; Starkie et al. 2001;
Ullum et al. 1994).
Taken together, obesity represents the ideal human model to elucidate whether IL6 mediates the effects of exercise on appetite regulation; and while direct comparisons
between lean and obese individuals have been conducted for the examination of exerciseinduced effects on appetite (Douglas et al. 2017; Marzullo et al. 2008; Ueda et al. 2009),
little to no work has been conducted to mechanistically explain such effects. Moreover, it
is important that experiments designed to observe the effects of exercise on appetite
regulation not be confined to the immediate post-exercise period (i.e., ≤90 min), as longer
observations (i.e., 90-150+ min) improve the utility and relevance of the findings.
Therefore, this study sought to determine whether exercise-induced increases in IL-6 are
involved in the appetite regulatory response post-exercise by examining appetiteregulatory hormonal and perceptual responses in obese and lean sedentary males before
exercise and for 2.5 hours post-exercise. Compared to the lean group we expected the
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obese to exhibit lower fasting concentrations of all appetite peptides but greater fasting IL6, along with a greater absolute exercise-induced increase in IL-6. Moreover, based on
previous findings we expected that post-exercise AG would decrease, PYY3-36 and active
GLP-1 would increase and that IL-6 would mediate these changes.

Methods
Participants - A total of 10 lean and 7 obese participants were recruited from Wilfrid
Laurier University and the University of Waterloo (refer to Appendix C for recruitment
details). An obese classification was based on the BMI standards (≥30 kg·m-2) for sex and
age as per the World Health Organization (2014) and on ethnic-specific waist
circumference values (≥94 cm unless Asian then ≥90 cm) as per the Canadian Diabetes
Association Clinical Practice Guidelines (Cheng and Lau 2013). A sedentary classification
(i.e., ≤150 min of moderate-vigorous physical activity·week-1) was based on results of both
the Physical Activity and Sedentary Behaviour Questionnaire (PASB-Q) and Modified
Leisure Time Physical Activity Questionnaire (mLTPAQ; Fowles et al. 2017). The
decision to selectively recruit males was based on recent evidence suggesting there are
differential sex-based responses in the anorectic peptides GLP-1 and PYY following both
sub- and supramaximal exercise (Hazell et al. 2017), and further bolstering this decision is
the fact potential confounding effects of the menstrual cycle on appetite regulation are only
beginning to be uncovered (McKie et al. 2018).
In addition to the criteria above, all participants were non-smokers and deemed
healthy as per the CSEP Physical Activity Readiness Questionnaire-Plus (PAR-Q+; Bredin
et al. 2013; Warburton et al. 2011). Participants were excluded from participating in the
study if they had a diagnosis of type II diabetes, uncontrolled hypertension, a history of
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cardiovascular disease, any contraindications to exercise or donating blood, if they were
taking any glucose lowering or immunomodulatory medications, or if they answered yes
to having any one of the 25 inflammatory conditions screened for at baseline (see Appendix
D for all screening tools).

Ethical approval was obtained from the Wilfrid Laurier

University and University of Waterloo Research Ethics Boards in accordance with the
standards of the 1964 Declaration of Helsinki. Prior to data collection informed consent
was obtained and all experimental details were fully explained to each participant.

Study design - All participants completed one familiarization session (~2.5 h) followed by
two experimental sessions (~5 h each) in a systematic rotational order using a 2x2 Latin
square design. Experimental sessions were separated by ≥7 days. The experimental
sessions consisted of one no exercise control (CTRL) and one moderate-intensity
continuous exercise session (EX). Blood samples were obtained, and perceptions of
appetite were measured at several time points throughout each trial (see Figure 3).
Participants arrived at the laboratory following a 12 h overnight fast and refrained from
physical activity, alcohol, and caffeine for ≥12 h before each experimental session. All
participants were instructed to consume ~250 mL of water before sleeping the night before,
and upon waking the day of each experimental trial in order to ensure euhydration among
all participants. This also served as a means to maintain blood plasma volume throughout
the fast.

Pre-experimental procedures - During the familiarization session anthropometric
measurements of height and weight were assessed using a standard mechanical scale
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(Health-o-meter Professional, Sunbeam Products, Inc., Illinois, USA) and waist
circumference was measured using a standard measuring tape. Additionally, participants
had measurements of resting heart rate (HR) and blood pressure (BP) taken using a Polar
HR monitor (FT1, Polar Electro, QC, Canada) and manual sphygmomanometer (Bronze
Series DS44, Welch Allyn, ON, Canada), respectively.
Participants also performed an incremental test to exhaustion on a Velotron cycle
ergometer (RacerMate, WA, USA) to determine their maximal rate of oxygen consumption
(V̇O2max).

Using an online breath-by-breath gas collection system (MAX II, AEI

Technologies, PA, USA) calibrated before each test using gases of known concentrations
and a 3 L syringe for flow, the rate of oxygen consumption (V̇O2) and carbon dioxide
production (V̇CO2) was measured. Participants were fitted with a silicon facemask
(Vmask, Hans Rudolph Inc., KS, USA) as well as a HR monitor to record beat-to-beat
activity using an online telemetry system (PT1, Polar Electro, QC, Canada).

All

participants completed a standardized 5 min warm-up consisting of pedalling at 50 Watts
(W) on the Velotron ergometer. The test then began with participants continuing to pedal
against a workload of 50 W with the workload increasing linearly by 1 W every 4 seconds
until the attainment of V̇O2max occurred. V̇O2max was be defined a priori as the greatest 30
s average in the presence of a plateau in V̇O2 values (<1.35 mL·kg-1·min-1) despite an
increase in workload. Secondary criteria for terminating the test included the pedal
cadence falling below 50 rotations per minute (rpm; Gillen and Gibala 2014; Gillen et al.
2016; Gillen et al. 2013) or two of the following: 1) a respiratory exchange ratio (RER)
greater than 1.15; 2) HR within ±10 beats per minute (bpm) of age predicted HR max
(defined as 220 bpm - participant age); or 3) complete participant exhaustion. This method

63

has been employed previously with overweight and obese individuals (Gillen et al. 2016)
and there is no empirical evidence suggesting excess body fat impairs O 2 delivery in obese
individuals (Wood et al. 2010).
Immediately following completion of the incremental test all participants
performed a 5 min cool-down at a self-selected pace and then sat quietly, resting for ~20
min to ensure HR and BP normalized. Then, a short (<10 min) constant work rate
verification test was completed at 100% of the workload attained during the incremental
test in order to verify the prior measurement of V̇O2max. This procedure follows current
recommendations (McKie and Hazell 2018; Poole and Jones 2017) and has been previously
employed in overweight and obese sedentary populations (Sawyer et al. 2015; Wood et al.
2010). Following this, participants again rested (for ~20 min) such that HR and BP
normalized. During this period, the appropriate workload for the EX session (65% V̇O2max)
was calculated using the ACSM general equation for cycle ergometry (V̇O2max (mL·kg1

·min-1) = workload (W) ÷ mass (kg) x 10.8 + 7.0 mL·kg-1·min-1). Participants then

remounted the Velotron a third time so the appropriate workload for the EX session could
be empirically verified with the metabolic cart. On average, the familiarization session
lasted 2-2.5 h.

Experimental procedures - Participants arrived at the laboratory for 0800 h following a 12
h overnight fast and remained in the laboratory for the next 5.5 h (Figure 3). At 0815 h a
resting blood sample was taken and following this, participants were served a standardized
breakfast equivalent to 29 kJ·kg-1 body mass. The macronutrient breakdown of the meal
was (68% CHO, 17% FAT, 15% PRO) and it was consumed with 500 mL of water.
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Participants were allotted 15 min to consume the meal (0815-0830 h) and 30 min to digest
its contents (0830-0900 h). At 0900 h a pre-exercise blood draw was taken and following
this the exercise protocol commenced. Exercise began with a 5 min standardized warmup at 50 rpm, followed by 60 min of continuous cycling at a workload set to elicit 65%
V̇O2max, ending with a 5 min standardized cool-down at 50 rpm. Water was provided ad
libitum during exercise. Following exercise participants sat quietly and rested with the
remaining blood draws being taken at 1040, 1140, and 1240 h, (0.5, 1.5, and 2.5 h postexercise). Perceptions of appetite were assessed using a visual analogue scale (VAS)
immediately before every blood draw. CTRL was identical to EX with the exception that
there was no exercise from 0900-1010 h, instead participants sat quietly.

Figure 3. Experimental timeline. Note: The 60 min EX session (at 65% V̇O2max) was
preceded by a 5 min warm-up and followed by a 5 min cool-down.

Blood processing & analysis - Lean participants laid in a supine position while blood
samples were collected for the measurement of AG, active GLP-1, PYY3-36, and IL-6.
Samples were obtained via an antecubital venipuncture using a 22-guage 1.25-inch needle
(Becton Dickinson Insyte; Becton, Dickinson & Company, UT, USA).

All obese
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participants had their blood samples collected for the measurement of the same analytes
via an indwelling 20-gauge 1.16-inch I.V. catheter (Becton Dickinson Insyte; Becton,
Dickinson & Company, UT, USA) inserted into the antecubital vein by a Registered Nurse.
The decision to catheterize obese participants was made due to the high likelihood of a
missed venipuncture brought about by excessive subcutaneous adiposity. At each time
point, two samples (3 mL whole blood each) were collected into separate pre-chilled
Vacutainer tubes (Becton, Dickinson & Company, NJ, USA) coated with 5.4 mg of
dipotassium ethylenediaminetetraacetic acid (K2 EDTA) anticoagulant. In the first tube,
40 μL of 4-(2-Aminoethyl) benzenesulfonyl fluoride hydrochloride (AEBSF; 25 mg·mL1)

per mL whole blood was added to prevent degradation of AG. In the other tube, 10 μL

of dipeptidyl peptidase-IV (DPP-IV) inhibitor and 500 kallikrein inactivator units (KIU)
aprotinin (Trasylol) per mL whole blood were added to prevent inactivation of GLP-1 and
ex-vivo conversion of PYY1-36 to PYY3-36. All tubes were gently inverted 10 times and
centrifuged at 3000 g for 10 min at 4° C. The plasma supernatant was then dispensed into
sterilized 2 mL microcentrifuge tubes (Santa Cruz Biotechnology, Inc., Texas, USA) with
the plasma from the AG Vacutainer being acidified by the addition of 100 μL of 1 M
hydrochloric acid (HCl) per mL plasma. All plasma supernatant was stored at -80° C until
analysis. Commercially available enzyme-linked immunosorbent assay kits were used to
determine plasma concentrations of AG (EMD Millipore, MA, USA), active GLP-1 (EMD
Millipore, MA, USA), PYY3-36 (Phoenix Pharmaceuticals, CA, USA), and IL-6 (R&D
Systems, MN, USA) according to the manufacturer’s instructions. All samples were
analyzed in duplicate, except for a random 25% which were run in triplicate, and batch
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analyzed for each participant to eliminate inter-assay variation. The average intra-assay
CV was: 7.9% for AG; 7.1% for PYY3-36; 10.4% for active GLP-1; and 5.4% for IL-6.

Perceptions of appetite - Using a VAS (see appendix F) perceptions of appetite including
hunger (i.e., “How hungry do you feel?”), fullness (i.e., “How full do you feel?”),
satisfaction (i.e., “How satisfied do you feel?”), and prospective energy intake (i.e., “How
much do you think you could eat?”), were measured (Flint et al. 2000; Islam et al. 2017).
The VAS required participants to place a vertical tick along a 100-mm horizontal line in
response to one of the above questions. The line was anchored at each end with contrasting
statements (i.e., “Completely” vs “Not at all”) and an overall appetite rating was quantified
as the mean value of the four appetite ratings after satisfaction and fullness were reverse
scored (Stubbs et al. 2000). This method has been successfully employed with obese
participants in previous research (Flint et al. 2001; Painchaud Guerard et al. 2016; Snoek
et al. 2004).

Measurement of sleep - Furthermore, to test the hypothesis that an altered sleep
duration/quality can disrupt appetite-regulatory responses, we screened participants using
the standardized Pittsburgh Sleep Quality Index (PSQI; Buysse et al. 1989), a 19-item
questionnaire designed to measure subjective sleep habits. The PSQI is comprised of seven
different sections, each generating a single score, and one cumulative total score. Each
individual criterion is weighed on a 0-3 interval scale with the total score being the sum of
the seven section scores producing an overall score from 0-21 with lower scores indicative
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of a healthier sleep quality. In addition, we had participants subjectively record their sleep
duration in a supplied log (see Appendix E) for 7 days following each experimental session.

Statistical analyses - All data were analyzed using the Statistical Package for the Social
Sciences version 24.0 (IBM SPSS Inc, Chicago, IL, USA) with figures generated in
GraphPad PRISM version 7.0 (GraphPad Software, La Jolla, CA, USA). Independent
samples t-tests were used to test for differences in baseline characteristics, performance
indices, fasting concentrations of all hormones within and between groups, and PSQI
results. Hormone concentrations and overall appetite scores were expressed in absolute
terms only. This decision was made entirely because the lean and obese groups exhibited
distinct differences in fasting hormone concentrations, rendering a comparison relative to
a fasting baseline (as is the norm in the literature) incorrect. The area under the curve
(AUC) was calculated using the trapezoidal approximation method when appropriate.
Three-way repeated measures mixed analyses of variance (3W-RM ANOVA) were used
to test for differences in appetite-regulating peptides, IL-6, and overall appetite. The
between subject’s factor was group with two levels (lean or obese) and the within subject’s
factors were session with two levels (CTRL or EX) and time with five levels (fasted, preexercise, 30-, 90-, and 150-min post-exercise). Two-way RM ANOVAs (group x session)
were used to compare AUC values and sleep log data.

Moderation analyses were

conducted to determine whether IL-6 influenced the anorexigenic effects of active GLP-1
and PYY3-36 or the orexigenic effects of AG on overall appetite at each post-exercise time
point. Moderation analyses were carried out for each group separately and then both
groups combined.

Pearson product-moment correlations were used to establish
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associations among select variables with correlation coefficients (r) classified as very weak
(.00–.19), weak (.20–.39), moderate (.40–.59), strong (.60–.79), or very strong (.80–1.0;
Fisher 1925). Partial eta-squared (ηp2) values are provided to supplement results of all
ANOVAs with a value of 0.01 considered the minimum important difference, 0.06
moderate and ≥0.14 large (Cohen, 1988). Fisher’s LSD tests were used post-hoc when
necessary. The level of significance was set at P<0.05 a priori and all data are presented
as the mean±standard deviation (SD).

Results
Statistical assumptions - Mauchly’s test of sphericity tests the null hypothesis that the
variances of the differences are equal. The results of this test indicated that the assumption
of sphericity was violated for active GLP-1 (χ2(9)=18.83, P=0.029), overall appetite
(χ2(9)=18.18, P=0.036), and IL-6 (χ2(9)=20.57, P=0.016) but not AG or PYY3-36. As such,
the Huynh-Feldt correction factor to the degrees of freedom for the active GLP-1, overall
appetite, and IL-6 3W-RM ANOVAs was used (Epsilon (ε)=0.609, 0.933, and 0.813,
respectively). This corrects the degrees of freedom such that the correct critical value for
the F-statistic is used to test the null hypothesis, it bears no effect on the F-statistic itself
(Laerd Statistics 2015). The assumption of homogeneity of variance was also violated, as
assessed by Levene’s test for equality of variance, for: IL-6 at 90 (F(1,10)=5.89, P=0.036)
and 150 (F(1,10)=8.62, P=0.015) min post-exercise, AG at 90 min during EX (F(1,10)=8.79,
P=0.014), active GLP-1 at 30 min during both CTRL (F(1,10)=21.84, P=0.001) and EX
(F(1,10)=15.32, P=0.003). The data were approximately normally distributed as assessed
using the Shapiro-Wilk test (P>0.05) and since the group sample sizes were equal and the
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3W-RM ANOVA is an omnibus test considered robust against heterogeneity of variance
(Laerd Statistics 2015), the analyses were run without transforming the data.

Participants - A total of 10 lean and 7 obese participants were recruited and successfully
pre-tested. However, one lean participant completed his first experimental session and
then withdrew from the study, while the remaining three lean participants withdrew after
completing their familiarization but prior to attending their first experimental session. One
obese participant attempted to complete his first experimental session twice, however the
Registered Nurses could not successfully draw blood due to excessive subcutaneous
adiposity and he was therefore let go from the study. As such, data are presented here for
6 lean and 6 obese sedentary males only, their demographic information can be found in
Table 1.
Participants were tested for the frequency with which they ate breakfast so as to
explain any potential variation in fasting peptide concentrations, however there were no
differences in the frequency of breakfast consumption reported between lean and obese
groups during CTRL (53.3±39.3 mm vs 53.0±29.1; P=0.987) or EX (51.2±38.6 vs
56.8±24.9; P=0.769) sessions respectively. There were also no differences within the lean
(P=0.688) and obese (P=0.492) groups between sessions (this data is not shown).
Table 1. Participant characteristics.
Lean Sedentary
(n=6)
Age (y)
20.7±3.0
BMI (kg·m-2)
23.2±2.7
Waist Circumference (cm)
84.3±10.4
V̇O2max (mL·kg-1·min-1)
37.4±6.5
Resting HR (beats·min-1)
74.±11
Systolic BP (mmHg)
113±16
Diastolic BP (mmHg)
79±8

Obese Sedentary
(n=6)
20.3±2.9
31.8±2.4
106.5±8.1
22.0±5.6
80±8
116±5
84±6

P-value
0.848
<0.001
0.001
0.002
0.338
0.685
0.228
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Performance measures - There were statistically significant differences between the lean
and obese groups for a number of parameters during the EX intervention itself (see Figure
4). Specifically, the lean group exercised at a greater absolute (lean: 117±29.8 W vs obese:
82.1±70.8; P=0.019, 95% CI [-62.8, -7.08]; Figure 4A), and relative workload (lean:
1.6±0.4 W·kg-1 vs obese: 0.9±0.1; P=0.003, 95% CI [-1.11, -0.29]; Figure 4B), while also
cycling with a faster cadence (lean: 59.0±5.4 rpm vs obese: 48.5±7.7; P=0.021, 95% CI [19.1, -1.97]; Figure 4C). However, there were no differences in distance cycled (P=0.589;
Figure 4D) or HR responses (P=0.243; Figure 4E) between groups.
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Figure 4. Performance indices from the EX session (60 min at 65% V̇O2max).
IL-6
Fasted: Mann-Whitney U tests were run (using an exact sampling distribution for U)
to test the null hypotheses that the distribution of fasted IL-6 values for obese and lean
males were equal during EX and CTRL. This was done after the distributions were
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deemed not similar via visual inspection. Fasted IL-6 concentrations during EX for the
obese group were significantly higher than the lean group (mean rank=9.5 vs 3.5; U=0,
P=0.002). Similarly, fasted IL-6 for CTRL was greater in the obese than lean (mean
rank=8.8 vs 4.2; U=4, P=0.026). Moreover, there were no differences between sessions
within the lean (P=0.098) and obese (P=0.103) groups (see Figure 5A).
Effects of exercise: There were no statistically significant interactions for group x time
x session (F(4,40)=0.51, P=0.711, ηp2=0.49), time x session (F(4,40)=2.58, P=0.058,
ηp2=0.205), time x group (F(4,40)=0.35, P=0.807, ηp2=0.034), and session x group
(F(1,10)=0.39, P=0.545, ηp2=0.038). There was also no statistically significant main
effect of group (F(1,10)=3.30, P=0.099, ηp2=0.248) but there was a main effect of time
(F(4,40)=7.18, P=0.001, ηp2=0.418) and a strong trend for a main effect of session
(F(1,10)=4.80, P=0.053, ηp2=0.324; see Figure 5B). Specifically, IL-6 tended to be
greater during EX (8.6±5.5 pg·mL-1) than CTRL (7.1±6.2; P=0.053, 95% CI [-0.026,
3.058]) with concentrations being greater at 30 (8.5±5.1), 90 (9.0±6.2), and 150
(8.5±6.7) min post-exercise compared to fasted (6.4±5.3; all P<0.05) and pre-exercise
(6.7±6.0; all P<0.05).
Area under the curve (AUC): There was no group x session interaction (F(1,10)=0.40,
P=0.542, ηp2=0.038) for the IL-6 AUC nor was there a main effect of group (F (1,10)=3.27,
P=0.101, ηp2=0.246), but there was a trend for a main effect of session (F (1,10)=4.54,
P=0.059, ηp2=0.312) with EX tending to be greater than CTRL (see Figure 5C).

72

P=0.002
P=0.103
P=0.098
P=0.026
LEAN

OBESE

Fasted IL-6 (pg·mL-1)

10
8

Figure 5. Fasted IL-6 (A), IL-6 over time
during each session (B), and the IL-6 AUC
(C). Note: a - significantly greater than
CTRL; b - significantly greater than
Fasted; c - significantly greater than PreEx.

6
4
2
0
CTRL

EX

P=0.053
EX a

CTRL

IL-6 (pg·mL-1)

25
20

P=0.001b,c

Obese

b,c

b,c

b,c

Lean

b,c

b,c

15
10
5

b,c
b,c b,c b,c

b,c b,c

0
d x
te e-E
s
F a Pr

30

90 150

d x
te e-E
s
F a Pr

30

90 150

IL-6 AUC (a.u.)

6000

4000

2000

0
CTRL

EX

P=0.059
73

Active GLP-1
Fasted:

There was a significant difference between fasting active GLP-1

concentrations in obese vs lean males for the EX session (9.7±3.6 pM·mL-1 vs 5.2±2.5;
P=0.031, 95% CI [-8.43, -0.51]) and a trend for the CTRL session (9.0±4.7 vs 5.0±1.1;
P=0.069). There were no differences within the lean (P=0.829) and obese (P=0.492)
groups between sessions (see Figure 6A).
Effects of exercise: Further, there were no statistically significant interactions for
group x time x session (F(4,40)=1.34, P=0.283, ηp2=0.118), time x session (F(4,40)=0.20,
P=0.861, ηp2=0.019), time x group (F(4,40)=0.97, P=0.429, ηp2=0.089), and session x
group (F(1,10)=1.43, P=0.259, ηp2=0.125). There was also no main effect of session
(F(1,10)=1.01, P=0.338, ηp2=0.092), but there was a main effect of time (F (4,40)=11.44,
P<0.001, ηp2=0.534) and a near effect of group (F(1,10)=4.96, P=0.050, ηp2=0.331) with
obese (9.3±3.5) having greater concentrations than lean (6.6±2.5). Specifically, active
GLP-1 was greater (all P<0.01) pre-exercise (10.6±3.1) than fasted (7.2±3.7), 30
(8.2±2.6), 90 (7.5±2.4), and 150 (6.2±2.9) min post-exercise, with 30 and 90 also being
greater than 150 (P<0.05; see Figure 6B).
Area under the curve (AUC): There was no statistically significant group x session
interaction (F(1,10)=3.73, P=0.082, ηp2=0.353) for the active GLP-1 AUC. There was
also no main effect of session (F(1,10)=0.76, P=0.403, ηp2=0.030) but there was a trend
for group (F(1,10)=4.71, P=0.055, ηp2=0.386; see Figure 6C).
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Figure 6. Fasted active GLP-1 (A),
active GLP-1 over time during each
session (B), and the active GLP-1 AUC
(C). Note: a - significantly greater than
lean; b - significantly greater than
Fasted; c - significantly greater than 30;
d - significantly greater than 90; e significantly greater than 150.
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PYY3-36
Fasted: There were no differences in fasting PYY 3-36 concentrations between obese
and lean groups for EX (1.0±0.5 ng·mL-1 vs 0.7±0.3; P=0.242) and CTRL (0.9±0.5 vs
0.8±0.3; P=0.468), respectively. There were also no differences within the lean (P =
0.149) and obese (P=0.167) groups between sessions (see Figure 7A).
Effects of exercise: There were no significant interactions for group x time x session
(F(4, 40)=0.94, P=0.452, ηp2=0.086), time x session (F(4,40)=0.69, P=0.602, ηp2=0.065), or
session x group (F(1,10)=3.40, P=0.095, ηp2=0.254), nor was there a main effect of session
(F(1,10)=2.72, P=0.13, ηp2=0.214). However, there was a significant time x group
interaction (F(4,40)=3.01, P=0.029, ηp2=0.232) with the lean group having greater PYY336

concentrations pre-exercise (0.78±0.27; P = 0.013, 95% CI [0.026, 0.174]), 30

(0.81±0.32; P = 0.003, 95% CI [0.057, 0.213]), and 90 (0.84±0.32; P = 0.004, 95% CI
[0.062, 0.252) min post-exercise compared to 150 (0.68±0.25). PYY3-36 was also
greater at 30 and 90 min relative to fasting (0.73±0.27; both P<0.05; see Figure 7B).
Area under the curve (AUC): For the PYY3-36 AUC there was no group x session
interaction (F(1,10)=2.94, P=0.117, ηp2=0.227), main effect of group (F(1,10)=0.751,
P=0.407, ηp2=0.07), or main effect of session (F(1,10)=3.22, P=0.103, ηp2=0.244; see
Figure 7C).
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AG
Fasted: There were no differences between the obese and lean groups for fasting AG
during the EX (262±188 pg·mL-1 vs 350±258; P=0.518) or CTRL (243±138 vs
376±262; P=0.296) sessions, respectively. There were also no differences within the
lean (P=0.671) and obese (P=0.433) groups between sessions (see Figure 8A).
Effects of exercise: There was a statistically significant group x time x session
interaction for AG (F(4,40)=4.25, P=0.006, ηp2=0.298) such that during CTRL the lean
group had greater AG (all P<0.05) at 90 and 150 min (498.9±315.4 and 589.8±61.5,
respectively) than fasted (376.4±262.1), pre-exercise (290.7±145),

and 30

(356.8±241.2). AG at 150 min post-exercise in the lean group was also different
between sessions (CTRL: 589.8±61.5 vs EX: 379.6±107.5; P=0.001, 95% CI [106.57,
313.89]). Similarly, AG at 150 min during EX was greater than 30 min post-exercise
(285.1±132.3 vs 144.5±67.4; P=0.028, 95% CI [18.27, 262.89]) in the obese group.
Lastly, there were differences between groups during CTRL at 90 (lean: 498.9±315.4
vs obese: 154.4±86.6; P=0.027, 95% CI [47.01, 642.04]) and 150 min (lean: 589.8±61.5
vs obese: 215.7±156.3; P<0.001, 95% CI [221.37, 526.99]), with a strong trend for 30
as well (lean: 356.8±241.2 vs obese: 138.1±58.5; P = 0.056). Similarly, there were
differences during EX at 30 min (lean: 308±154 vs obese: 144.5±67.4; P= 0.039, 95%
CI [10.52, 316.41]) with a strong trend for a difference at 90 (lean: 421.5±230.5 vs
obese: 206.6±77.8; P = 0.056; see Figure 8B).
Area under the curve (AUC): There was a group x session interaction (F (1,10)=5.45,
P=0.042, ηp2=0.272) for the AG AUC with the lean having greater values during CTRL
than obese (Figure 8C).
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Figure 8. Fasted AG (A), AG over time
during each session (B), and the AG
AUC (C). Note: a - significantly greater
than Fasted; b - significantly greater than
Pre-Ex; c - significantly greater than 30;
$ - significantly different than CTRL; # significantly greater than obese group.
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Overall appetite
Effects of exercise: For overall appetite, there were no interactions for group x time x
session (F(4,40)=0.66, P=0.613, ηp2=0.062), time x session (F(4,10)=0.14, P=0.959,
ηp2=0.014), session x group (F(1,10)=0.35, P=0.567, ηp2=0.034), or time x group
(F(4,10)=1.95, P=0.121, ηp2=0.163). There were also no main effects for group (F (1,10)=0.00,
P=0.956, ηp2=0.00) or session (F(1,10)=0.76, P=0.405, ηp2=0.07), but there was a main effect
of time (F(4,40)=16.13, P<0.001, ηp2=0.617). Specifically, overall appetite was greater
fasted (81.2±16.8) compared to pre-exercise (43.8±23.7; P<0.001, 95% CI [22.14, 52.63]),
30 (55.4±16.2; P=0.001, 95% CI [12.95, 38.55]), and 90 (65.3±15.7; P=0.012, 95% CI
[4.41, 27.34]) min post-exercise, but not 150 (77.9±14.2; P=0.451). 90 and 150 min were
also greater than pre-exercise (both P<0.01) and 30 (both P<0.05), with 150 being greater
than 90 as well (P=0.01, 95% CI [3.77, 21.34]; see Figure 9A).
Area under the curve (AUC): There was no statistically significant group x session
interaction for the overall appetite AUC (F (1,10)=0.08, P=0.786, ηp2=0.008), nor was there
a main effect of session (F(1,10)=0.39, P=0.544, ηp2=0.038) or group (F(1,10)=0.016, P=0.903,
ηp2=0.002; see Figure 9B). The results for each individual appetite perception can be found
in Appendix G.
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Sleep responses - There were no statistically significant differences between groups for
any individual component of the PSQI or PSQI total score (see Figure 10 and Table 2).
However, subjectively recorded sleep log data revealed a trend for a main effect of group
(F(1,10)=4.71, P=0.058) such that the obese group tended to sleep more than the lean
irrespective of session (see Figure 10 left panel). There was also a statistically significant
group x session interaction (F(1,10)=6.43, P=0.032) for nightly sleep disturbances although
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Figure 10. Average weekly sleep duration (left) and frequency of sleep disturbances (right) for both groups.

Table 2. Pittsburgh Sleep Quality Index (PSQI) results for lean and obese groups.
Lean Sedentary
Obese Sedentary
P-value
(n=6)
(n=6)
PSQI-sleep duration
0.7±0.8
0.2±0.4
0.209
PSQI-sleep disturbances
0.8±0.4
1.2±0.4
0.188
PSQI-sleep latency
0.8±1.0
1.7±1.0
0.183
PSQI-daytime dysfunction
0.8±0.8
1.3±1.0
0.361
PSQI-habitual sleep efficiency
1.3±1.2
0.5±0.8
0.196
PSQI-sleep quality
1.3±0.5
1.0±0.6
0.341
PSQI-medication use
0.5±0.8
0.0±0.0
0.174
PSQI-total score
6.3±3.4
5.8±3.4
0.806
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Moderation analyses - At 30 min post-exercise there was a strong trend for IL-6 to
moderate the appetite suppressing effects of AG on overall appetite, albeit in the lean group
only. The model (F(3,2)=18.88, P=0.051, R2=0.97) revealed that 97% of the variance in
overall appetite for the lean group at this time point was explained by the terms AG, IL-6,
and AG x IL-6. Refer to Table 3A for predictive equations and Table 3B for the conditional
effects for the interaction term AG x IL-6.

Table 3A. Predictive equations for the lean group at 30 min post-exercise.
Term
Slope (b)
t-critical(df)
P-value
AG
0.37
t(2)=4.36
0.049
IL-6
8.99
t(2)=5.66
0.030
AG x IL-6
-0.03
t(2)=-3.49
0.073

Table 3B. Conditional effects for the AG x IL-6 interaction
Term
Slope (b)
t-critical(df)
AG for low [IL-6]
0.14
t(2)=5.59
AG for avg [IL-6]
0.06
t(2)=2.92
AG for high [IL-6]
-0.06
t(2)=-1.30

P-value
0.031
0.100
0.323

IL-6 moderated the effects of AG on overall appetite in both groups at 90 min postexercise with the model explaining 63% of the variation in overall appetite (F (3,8)=4.48,
P=0.040, R2=0.63). The predictive equations can be found in Table 4A with the conditional
effects being found in Table 4B.

Table 4A. Predictive equations for both groups at 90 min post-exercise.
Term
Slope (b)
t-critical(df)
AG
0.16
t(8)=2.81
IL-6
4.46
t(8)=2.74
AG x IL-6
-0.01
t(8)=-2.37

P-value
0.023
0.025
0.045
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Table 4B. Conditional effects for the AG x IL-6 interaction
Term
Slope (b)
t-critical(df)
AG for low [IL-6]
0.11
t(8)=2.91
AG for avg [IL-6]
0.05
t(8)=2.35
AG for high [IL-6]
-0.01
t(8)=-0.42

P-value
0.020
0.047
0.686

There was also a trend for IL-6 to moderate the anorexigenic effects of PYY 3-36 on
overall appetite for the obese group only at 90 min post-exercise, with the model explaining
95% of the variance in overall appetite (F (3,2)=12.00, P=0.078, R2=0.95). The predictive
equations for PYY3-36, IL-6 and the PYY3-36 x IL-6 interaction can be found in Table 5A,
with the results of the conditional effects for the interaction being found in Table 5B.
Table 5A. Predictive equations for both groups at 90 min post-exercise.
Term
Slope (b)
t-critical(df)
PYY3-36
90.64
t(2)=3.52
IL-6
33.03
t(2)=4.49
PYY3-36 x IL-6
-23.60
t(8)=-4.08

Table 5B. Conditional effects for the PYY3-36 x IL-6 interaction
Term
Slope (b)
t-critical(df)
PYY3-36 for low [IL-6]
-5.85
t(2)=-0.92
PYY3-36 for avg [IL-6]
-97.06
t(2)=-4.43
PYY3-36 for high [IL-6]
-193.11
t(2)=-4.29

P-value
0.072
0.046
0.055

P-value
0.455
0.047
0.050
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Correlations - Since there were no effects of session on sleep duration, the sleep duration
from each experimental session was averaged for each group and used for correlational
analyses. There was a statistically significant strong positive association between BMI and
average sleep duration (r=0.68, P=0.016; Figure 11A). There was also a very strong
negative association between BMI and V̇O2max (r=-0.82, P=0.001; Figure 11B). There
were no statistically significant associations observed between BMI and average fasting
concentrations of active GLP-1 or AG (both P>0.05; Figure 11C and D, respectively),
although there was a strong trend for a positive association with PYY 3-36 (r=0.56, P=0.056;
Figure 11E). Furthermore, there were strong observable trends for an association between
average sleep duration and fasted active GLP-1 (r=0.57, P=0.053), and AG (r=-0.52,
P=0.083; Figure 11F and G respectively), but not fasted PYY3-36 (P= 0.682; Figure 11H).
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Figure 11. Pearson product-moment correlations (r) between BMI and: average sleep duration (A),
V̇O2max (B), fasted concentrations of active GLP-1 (C), AG (D), and PYY3-36 (E). Also shown are
correlations between average sleep duration and: fasted concentrations of active GLP-1 (F), AG (G),
and PYY3-36 (H). Note: red circles denote obese participants and black circles denote lean participants.
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Discussion
Obesity is associated with chronic low-grade inflammation characterized by
elevated levels of the proinflammatory cytokine IL-6 (Trayhurn and Wood 2004). IL-6
has demonstrated anorexigenic effects in animal (Ellingsgaard et al. 2011) and cell culture
models (Chew et al. 2014; Ellingsgaard et al. 2011), however these results have not been
translated into a human model of obesity. As such, the current investigation directly
compared the effects of cycling for 60 min at 65% V̇O2max between lean and obese
sedentary males to examine whether exercise-induced increases in IL-6 were involved in
the regulation of appetite post-exercise. We observed little difference in the appetiteregulatory response following EX which is in line with previous work comparing lean and
obese males (Douglas et al. 2017; Marzullo et al. 2008; Ueda et al. 2009). Importantly,
we failed to observe the potent appetite-inhibitory effects previously ascribed to IL-6
(Chew et al. 2014; Ellingsgaard et al. 2011), which was contrary to our initial hypothesis
but congruent with recent literature (Christiansen et al. 2018; Lang Lehrskov et al. 2018).

IL-6 - In accordance with our hypotheses, fasting IL-6 concentrations (9.1 pg·mL-1 vs 3.7
on average) and absolute exercise-induced increases in IL-6 (post-exercise average of 12.2
pg·mL-1 vs 7.4) were greater in the obese group, yet the relative increase was greater in the
lean group. Relative to baseline, the fold changes in the lean and obese groups at 30 min
post-exercise were 2.02- and 1.29-fold respectively, further increasing to 2.04- and 1.34fold at 90 min before declining. Similar to previous work (Slusher et al. 2015), we
observed protracted increases in IL-6 at 30 and 90 min post-exercise, yet our concentrations
appear to be of a much smaller magnitude than the 2- to 9-fold increases reported
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previously (MacDonald et al. 2003; Nybo et al. 2002; Starkie et al. 2001; Ullum et al.
1994). However, to allow for a direct comparison key methodological differences need be
considered.

The aforementioned studies were performed in lean moderately-to-well

trained men with baseline IL-6 concentrations as low as 0.8-1.5 pg·mL-1 (MacDonald et
al. 2003; Starkie et al. 2001) and as high as 51.0 pg·mL-1 (Ullum et al. 1994), by
comparison our lean sedentary group was 3.9±0.6 pg·mL-1. In fact, upon excluding those
studies which exhibit key methodological differences including: arterio-venous sampling
(Nybo et al. 2002), pre-exercise carbohydrate loading (Starkie et al. 2001) and pre-exercise
glycogen depletion (MacDonald et al. 2003), the 2.02-fold change observed in our lean
group is in line with the 1.63- and 2.13-fold increases observed by others (Slusher et al.
2015; Ullum et al. 1994). Similarly, the 1.29-fold increase in IL-6 observed in our obese
group 30 min post-exercise was similar to the 1.17-fold increase observed immediately
post-exercise following 30 min of continuous running at 75% V̇O2max in obese males and
females (Slusher et al. 2015). Those authors observed a protracted increase such that 120
min post-exercise the fold change was 1.24 which parallels the 1.34-fold change we
observed 90 min post-exercise and is nearly identical to the 1.21-fold change observed 150
min post-exercise in the current study. However, a previous study (Christiansen et al.
2013) reported a 3.5-fold increase in IL-6 immediately post-exercise in overweight/obese
men and women, albeit following 120 min of cycling at 55-60% HRmax which likely
explains the greater exercise-induced IL-6 secretion (Fischer 2006). Therefore, our postexercise IL-6 concentrations (in both groups) are comparable to those in the literature when
key methodological differences are taken into account. While some studies include male
and female participants (Christiansen et al. 2013; Slusher et al. 2015) future work should
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seek to elucidate potential sex-based differences in IL-6 secretion in light of recent
evidence suggesting muscle-derived IL-6 exhibits distinct sex-based effects on metabolism
(Ferrer et al. 2014).

Active GLP-1 and PYY3-36 - Contrary to our hypotheses, fasting active GLP-1 was greater
in the obese group and fasted PYY3-36 was not different. Moreover, there was a trend for
a moderately positive association between BMI and fasted PYY 3-36 (r=0.56; Figure 11E)
which is in direct opposition to previous work reporting a strong negative association
between BMI and total fasting PYY (r=-0.84; Batterham et al. 2003). This might suggest
that an increase in BMI results in a deficiency in the synthesis and/or secretion of PYY,
thus explaining their observations. It is important to note that the participants in that study
were ~10 years older than those in our current investigation, thus it is possible that older
obese individuals demonstrate such a deficiency whereas younger ones do not, simply
because they have had a greater exposure to the averse metabolic side effects of an
increased BMI. In agreement with this hypothesis is data from humans (Adrian et al. 1986)
and animals (Tovar et al. 2004) clearly demonstrating that PYY declines as age increases,
irrespective of sex.
There were however no observable effects of exercise on active GLP-1 or PYY3-36
within or between groups. While this is both contrary to some studies (Broom et al. 2009;
Douglas et al. 2017; Islam et al. 2017; Ueda et al. 2009) yet in line with others (Hazell et
al. 2017; Hunschede et al. 2017) it does agree with the conclusion of a recent meta-analysis
(Douglas et al. 2016) that exercise in participants with obesity (irrespective of intensity,
mode, duration etc.) exerts no effects on total concentrations of either peptide. Importantly
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however, the present investigation measured the active concentrations of both GLP-1 and
PYY where previous studies (Batterham et al. 2003; Broom et al. 2009; Douglas et al.
2017; Hazell et al. 2017; Hunschede et al. 2017; Islam et al. 2017; Martins et al. 2007;
Ueda et al. 2009) all measured total concentrations of one or both peptides. As such, direct
comparisons of results can be difficult, if not incorrect, given the unknown conversion rates
of inactive to active GLP-1/PYY and the fact that only the active peptides actually exert
appetite-regulatory properties (Martins et al. 2015). Subtle differences like these, along
with others including study design, sample collection/preparation and measurement all
offer potential explanations for discrepant results between studies (Chandarana et al. 2009).
The results of the moderation analysis led us to refute our hypothesis that IL-6
would be positively related to exercise-induced increases in active GLP-1, as IL-6 had no
influence on the effects of GLP-1 at all. While the original hypothesis that IL-6 would
mediate the effects of exercise on GLP-1 was based on animal and cell culture models
demonstrating IL-6 potently stimulates secretion of GLP-1 (Ellingsgaard et al. 2011),
recent animal (Christiansen et al. 2018) and human studies (Lang Lehrskov et al. 2018)
have shown otherwise. It is highly likely the more recent studies (Christiansen et al. 2018;
Lang Lehrskov et al. 2018) and ours have demonstrated no effect of IL-6 on GLP-1 given
the acute nature of IL-6 exposure. In contrast, Ellingsgaard et al. (2011) injected IL-6 into
mice twice daily for 7 days and incubated pancreatic cell cultures with IL-6 for 4 days, all
of which increased GLP-1 secretion markedly. Therefore, in order to observe the potent
GLP-1 stimulatory effects previously ascribed to IL-6 chronic exercise training, of a
sufficient intensity and duration to elevate IL-6, might be necessary. In terms of PYY3-36,
there was a strong trend (P=0.055) for IL-6 to moderate the effects of PYY3-36 on overall
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appetite at 90 min post-exercise in the obese group. While there was no statistically
significant effect for the low IL-6 concentration (see Table 5B), in the presence of average
IL-6 (8.0 pg·mL-1) every unit increase in PYY3-36 decreased appetite by 97 units, with a
further reduction by 193 units when the IL-6 concentration was high (12.0 pg·mL-1). Taken
together, this data indicates that with increasing concentrations of IL-6 there should be a
reduction in overall appetite as per the anorectic effects of PYY 3-36, however we failed to
observe such effects.

AG - Fasted AG was not different between groups which was contrary to our initial
hypothesis. Moreover, we observed decreased AG in the lean group at 150 min during EX
(379.6±107.0 pg·mL-1) compared to CTRL (589.8±61.5), but AG at this time point was
not different from the obese group which exhibited no effect of EX at all. This suggests
that the exercise was effective at inducing an appetite-suppressive effect in the lean group,
confirmed by the nearly significant difference in the lean AUC from CTRL to EX
(105718±48296 a.u. vs 92800±37951, respectively; P=0.068; trend not shown on Figure
7C). These observations are comparable to previous work demonstrating significant
reductions in AG following 30 min of cycling at 70% V̇O2max (Hunschede et al. 2017) and
a physically exhausting cycling protocol (Marzullo et al. 2008). However, the former study
reported no differences between lean and obese groups while the latter reported distinct
differences. More recently, 60 min of treadmill running at 60% V̇O2max had no effect on
AG in lean or obese males (Douglas et al. 2017) which supports earlier reports (Martins et
al. 2007; Ueda et al. 2009). However, the key difference between these studies seems to
be exercise intensity which could account for the differential AG responses. In fact,

91

pancreatic cell cultures treated with IL-6 demonstrate a clear dose- and time-dependent
down-regulation of ghrelin mRNA expression (Chew et al. 2014) and given IL-6 increases
in an intensity and time dependent manner (Fischer 2006) it makes sense that we (Islam et
al. 2017) and others (Marzullo et al. 2008) have observed decreases in AG utilizing
exercise intensities of ≥65% V̇O2max while others employing 50-60% V̇O2max observe no
change. In lean men, cycling at 65% HRmax for 60 min had no effect on AG (Martins et al.
2007), meanwhile we have previously demonstrated that both 30 min at 85% V̇O2max and
traditional 30 s running SIT reduce AG to a greater degree than 30 min of running at 65%
V̇O2max (Islam et al. 2017). Thus, the idea of an intensity threshold for the exercise-induced
suppression of AG is tempting although the evidence to support this in obese individuals
seems inconclusive at present. Lastly, it has been noted that exercise-induced suppression
of AG in obesity is trivial but seems to increase with BMI (Douglas et al. 2016). Given
the BMI of the obese group in the present investigation was only 31.8 kg·m-2 and thus on
the lower end of the obesity spectrum, it is plausible that the degree of obesity here was
not sufficient enough to drive the suppression of AG seen elsewhere in the literature.
Furthermore, the mRNA expression of ghrelin, the GOAT enzyme, and the ghrelin
GHSR are down-regulated in obesity (Briggs et al. 2010) leading to markedly lower plasma
AG concentrations (Cummings et al. 2002; Tschop et al. 2001b), meanwhile under normal
physiological conditions increased AG concentrations suppress glucose-stimulated insulin
secretion (Tong et al. 2010). Therefore, despite any significant group differences (see
Figure 8) we hypothesize that AG is lower in obesity not in an effort to promote less drive
to eat and therefore decrease EI, but to promote increased insulin secretion in a
glucoregulatory manner. This is highlighted by evidence demonstrating that reductions in
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circulating AG concentrations occur secondary to the development of obesity (i.e., after
hyperglycemic conditions set in) rather than in response to a short-term positive energy
status (Parry et al. 2017). As such, AG concentrations in our obese group might not have
changed following exercise in an effort to promote insulin secretion and thus euglycemia.
This remains a speculation although it would not be inappropriate to assume our obese
group had some degree of hyperglycemia based on the vast body of obesity-related
literature (Bray 2004).
Lastly, there was a strong trend (P=0.073) for IL-6 to moderate the effects of AG
on overall appetite in the lean group only at 30 min post-exercise, which makes sense given
the lean group had greater IL-6 at 30 min post-exercise than the obese (Δ absolute IL-6
from baseline was 4.0 pg·mL-1 vs 2.8, respectively). An examination of the conditional
effects of the interaction term (Table 3B) indicated that in the presence of low IL-6
concentrations (8.9 pg·mL-1 in the case of this model), every unit increase in AG was
accompanied by a 0.14 unit increase in overall appetite. While the effects for average and
high IL-6 concentrations were not statistically significant at this time point, it would seem
increasing IL-6 concentrations lead to a dampening of the orexigenic effects of AG on
appetite. This was in fact the case at 90 min post-exercise where IL-6 moderated the effects
of AG on overall appetite in both groups (P=0.045), perhaps not surprising given IL-6
concentrations peaked at 90 min post-exercise in both groups. Again, an examination of
the conditional effects revealed that as IL-6 concentrations increased there was a reduction
in the effects of AG on overall appetite (see Table 4B). Specifically, for low IL-6
concentrations (4.8 pg·mL-1) every unit increase in AG increased overall appetite by 0.12
units, however in the presence of average IL-6 concentrations (10.4 pg·mL-1) this
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decreased to 0.05 units. While there were no other significant conditional effects these
results do indicate that increasing concentrations of IL-6 moderate the relationship between
AG and overall appetite. These effects could be explained by previous work demonstrating
that IL-6 dose-dependently reduces AG mRNA expression in pancreatic cell cultures
(Chew et al. 2014).

Sleep duration and disturbances - Interestingly, we observed that the obese group slept
more on average than the lean group and that they also had more frequent sleep
disturbances, despite the PSQI indicating no differences in sleep quality between groups.
Sleep duration was also positively associated with BMI (r=0.68; Figure 11A) and trended
to be associated positively with fasted active GLP-1 (r=0.57; Figure 11F), but negatively
with AG (r-0.52; Figure 11G). Metabolic, polysomnographic, and subjectively recorded
sleep data compiled from the longitudinal Wisconsin Sleep Cohort Study (Taheri et al.
2004) revealed that a short sleep duration is associated with an increased BMI and elevated
concentrations of total ghrelin. While we did observe an inverse trend for AG and sleep
duration we observed the exact opposite with regard to sleep duration and BMI. It is
possible that our sleep data was confounded by the fact our sample included only
University aged students, thus deviating from the population-based sample in the
Wisconsin Sleep Cohort Study, or perhaps because we measured acylated (active) and not
total (acylated + des-acylated) ghrelin specifically. Moreover, it has been demonstrated in
animal models that AG induces wakefulness and less REM sleep (Tolle et al. 2002) perhaps
via an increased orexigenic drive to eat. Therefore, it might very well be that sleep duration
tends to be shorter when AG concentrations are elevated because one is primed to eat, a
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behavior which cannot occur during sleep. However, whether one might sleep less because
of increased AG or have increased AG because they sleep less remains unknown.

Perceptions of appetite - We observed no difference in the frequency of breakfast
consumption between groups which is an important outcome to assess given skipping
breakfast has been linked to a greater GLP-1 and PYY response at subsequent meals, along
with compensatory increases in EI later in the day (Astbury et al. 2011). Contrary to recent
reports (Deighton and Stensel 2014; Douglas et al. 2017; Goltz et al. 2018), we observed
no difference in overall appetite between lean and obese males during CTRL and EX.
Moreover, overall appetite during EX was not different than CTRL for either group and
exhibited similar prandial patterns before peaking at 150 min (see Figure 9A). Perhaps
most notable is that the obese group exhibited peptide concentrations consistent with a
signal for a reduction in appetite, yet they were as hungry following 60 min of cycling at
65% V̇O2max as they were during CTRL, possibly suggesting that there may be a discord
between appetite perceptions and peptides in obesity. However, other variables such as
non-homeostatic food cues and psycho-behavioral food tendencies are known to affect
appetite (Tulloch et al. 2015), and since we did not assess these outcomes we cannot be
sure whether they confounded our participants’ perceptions of appetite.

Limitations
There are several limitations to consider when interpreting the findings of this
study. First, we did not allow for an acclimation to the cannula following its insertion
before obtaining the fasted blood sample in our obese participants and as such may have
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artificially increased the potential confounding effects of study stress on appetite-related
parameters (Chandarana et al. 2009).

We also did not measure hematocrit and/or

hemoglobin in the present investigation, and as such were unable to correct peptide
concentrations for changes in plasma volume over time. Had we made these corrections
we could have determined the impact of MICT on the expression/secretion of these
peptides in the plasma, whereas our approach simply allowed for a determination of
changes in an absolute volume of a fraction of the total plasma. Importantly, this represents
what the cells would be exposed to physiologically however it does not account for shifts
in fluid balance with exercise. Moreover, evidence is emerging that venous GLP-1
concentrations are lower than in arterialized blood (Asmar et al. 2017) and despite the fact
fasted AG has been shown to be similar between venous and arterialized blood (Goodyear
et al. 2010; Martin et al. 2011) there has been no investigation to determine whether the
concentrations of either of these peptides, or PYY3-36 and IL-6, are lower in venous samples
post-exercise. Furthermore, although we sought to examine the effects of exercise on
appetite beyond the immediate post-exercise period we may have missed small fluctuations
in the magnitude of peptide concentrations by not taking more frequent samples, or more
samples over a further protracted period. Lastly, our sample is relatively small, and the
characteristics of our sample preclude any generalization beyond lean and obese sedentary
males of the age and demographics studied.

Conclusion
To our knowledge only 3 prior investigations have directly compared the effects of
moderate-intensity aerobic exercise on appetite-regulatory peptides between lean and
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obese sedentary males (Douglas et al. 2017; Marzullo et al. 2008; Ueda et al. 2009), with
the current study representing the first attempt at establishing a mechanistic explanation
for the effects of exercise on appetite in these cohorts. We observed a transient reduction
in AG for the lean group post-exercise and preliminary evidence that IL-6 moderates the
orexigenic effects of AG on appetite. We also showed here that obesity results in an
impaired metabolic and behavioral programming consistent with an increased state of
inflammation, abnormal sleep habits, and reduced cardiorespiratory fitness. Given these
results are preliminary the probable involvement of IL-6 in human appetite-regulation
remains unknown. Future work should expand on the data collected here in order to
establish a scientifically sound conclusion as to whether or not IL-6 mediates the effects of
exercise on appetite regulation in humans.
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CHAPTER 3:
CONCLUSIONS AND FUTURE DIRECTIONS
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Conclusions
This study was designed to determine whether the pro-inflammatory cytokine
interleukin (IL)-6 mediates the anorexigenic effects of moderate-intensity aerobic exercise
on appetite regulating peptides in humans. This work served as a direct extension of
previous animal and cell culture experiments that demonstrated IL-6 exerts appetiteinhibitory effects by dose-dependently down regulating ghrelin mRNA expression ex vivo
in pancreatic cells, while also increasing GLP-1 secretion ex vivo from GLUTag cells and
in vivo from mouse enteroendocrine L cells (Chew et al. 2014; Ellingsgaard et al. 2011).
To accomplish this, we chose to use an obese human model given obesity is associated
with a chronic state of low-grade inflammation, characterized by increased IL-6
concentrations at rest (Bastard et al. 2000; Trayhurn and Wood 2004). Further, by having
obese participants complete a long duration moderate-intensity aerobic exercise protocol
(60 min cycling at 65% V̇O2max) we were able to further increase their endogenous IL-6
concentrations and study the consequent effects of IL-6 on appetite-regulating peptides
post-exercise relative to a lean sedentary control group and a non-exercising control
session.
In line with our hypothesis and previous literature (Bastard et al. 2000; Bruunsgaard
et al. 1997) we observed greater fasted IL-6 concentrations in our obese group compared
to lean. We also observed greater fasted active GLP-1 concentrations in the obese group
with no difference in fasted AG or PYY 3-36, which was contrary to what we expected.
Previous literature shows that the total secretion of GLP-1 is downregulated in obesity
(Holst 2006; Naslund and Hellstrom 1998), as is PYY (Batterham et al. 2003; le Roux et
al. 2006), and AG (Callahan et al. 2004; Cummings et al. 2002; English et al. 2002) which
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has already been discussed. However, at least in the case of PYY, the presence of fasting
differences seems controversial (Stock et al. 2005) with the duration of the fast known to
markedly impact plasma concentrations (Tovar et al. 2004). Moreover, leptin stimulates
GLP-1 secretion dose-dependently in mice and when fed a high-fat diet, mice become
hyperleptinemic, obese, and then develop leptin resistance (Anini and Brubaker 2003). It
is this leptin resistance that is thought to explain the low fasting concentrations and
impaired post-prandial release of GLP-1 in obesity. However, we observed elevated
fasting GLP-1 concentrations in our obese group, leaving us to hypothesize that these obese
individuals might be hyperleptinemic but not yet leptin resistant. While we did not assess
this and therefore cannot conclude this is the case, their lack of leptin resistance would
suggest a moderate case of obesity (average BMI for obese group was 31.8 kg·m-2), as
leptin is strongly correlated with an increase in BMI due to its resistance (Naslund et al.
2000).
Expectedly, and in accordance with previous literature (Christiansen et al. 2013;
Slusher et al. 2015), the absolute exercise-induced increase in IL-6 was greater in the obese
with the relative increase being greater in the lean. Interestingly, despite the relative
magnitude of change being greater in the lean group their highest IL-6 concentration (8.0
pg·mL-1, a 200% increase from fasted) was still not equal to the lowest IL-6 concentration
in the obese group which was their fasting value of 9.6 pg·mL-1. This clearly highlights
the presence of systemic inflammation in our obese group, undoubtedly due to their excess
adiposity (Trayhurn and Wood 2004). We did observe an exercise-induced decrease in
AG, which is what we expected based on previous reports (Deighton et al. 2013; Islam et
al. 2017; Shiiya et al. 2011). However, this was only the case for the lean group with 150
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min post-exercise being different vs CTRL. Still, this does suggest that the acute exercise
bout was successful in promoting a decline in the orexigenic drive to eat post-exercise.
Contrarily, there was no effect of exercise on AG in the obese group which has been
consistently demonstrated in the literature (Douglas et al. 2017; Ueda et al. 2009).
Interestingly, the orexigenic drive to eat in the obese group was not different from CTRL
even after exercising at 65% V̇O2max for 60 min. The discrepant AG results might be
explained by considering that the exercise was not matched for EE between groups. Based
on rough estimates using the average 65% V̇O2max of each group and assuming 5 kcal
expended per L of O2 consumed, the lean group expended ~819 kcal during the 60 min
exercise session whereas the obese group only expended ~640 kcal. In order for the EE to
have been matched the obese group would have had to cycle for an additional 17 min, all
else equal.

Given AG is thought to decrease during/following exercise due to

gastrointestinal ischemia which decreases the acetylation of ghrelin by GOAT (Hazell et
al. 2016; Yang et al. 2008), it is possible this occurred to a lesser extent in the obese group.
Furthermore, there were no observable effects of exercise on active GLP-1, PYY3-36, or
overall appetite in both groups, with no group differences either. Collectively, this suggests
that the acute exercise bout had no effect whatsoever on the obese but transiently decreased
the drive to eat in the lean group. This is in line with the current literature reporting very
little difference between lean and obese appetite responses following MICT (Douglas et
al. 2016; Douglas et al. 2017; Marzullo et al. 2008; Ueda et al. 2009).
Unfortunately, due to the lack of exercise-induced changes in appetite peptides we
were unable to carry out what would have been the primary statistical test (a mediation
analysis) to answer our research question, “does IL-6 mediate the effects of exercise on
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appetite regulation?” By conducting a mediation analysis, we would have been able to test
whether the established relationship between exercise-induced increases in active GLP-1
and the consequent decreases in overall appetite could be explained by the addition of a
third mediating variable, IL-6. We would have conducted this analysis for PYY3-36 and
AG as well however our dataset violated key statistical assumptions (Baron and Kenny
1986). Instead, we were able to conduct a moderation analysis which simply indicates
whether or not the addition of a third moderating variable influences the relationship
between the predictor and outcome. In this case, we ran moderation analyses using active
GLP-1, PYY3-36, and AG as the predictors for the outcome variable overall appetite with
the moderator being IL-6. Contrary to previous evidence (Chew et al. 2014; Ellingsgaard
et al. 2011) and partly due to the lack of exercise-induced increases in active GLP-1, we
observed no moderating effect of IL-6 on the relation between active GLP-1 and overall
appetite. This is in line with very recent evidence reporting no acute stimulatory effect of
IL-6 on human (Lang Lehrskov et al. 2018) and animal (Christiansen et al. 2018) GLP-1
secretion. However, we did observe time-point specific effects of IL-6 on the relations
between both AG and PYY3-36 on overall appetite. Specifically, we found that increasing
IL-6 concentrations influenced the strength of these relationships such that it favored a
reduction in overall appetite.
Furthermore, we clearly outlined the abnormal sleeping behaviours of the obese
group and showed that on average they slept longer, and self-reportedly had more frequent
sleep interruptions despite being classified as not different from the lean group in terms of
sleep quality according to the PSQI. While their sleep patterns seemed to influence their
hormonal milieu (or vice versa) there is a potential confounding effect that our

110

experimental design could have had due to the fact that it began at 0800 h and lasted until
1240 h. Most of our obese participants reported sleeping >10 h per day and were not used
to waking up so early, let alone eating a standardized meal at 0815 h. As such, we cannot
be sure whether our experiment, by design, disrupted the hormonal milieu of the
participants and potentially confounded our results. In fairness, most if not all obesityrelated appetite studies share similar designs however we did selectively recruit students
who are known to sleep less on average (Medeiros et al. 2001; Veldi et al. 2005).
In conclusion, this study failed to demonstrate whether IL-6 is capable of mediating
the effects of exercise on appetite-regulatory peptides, however we did show that MICT
leads to a transient suppression of AG in lean but not obese individuals with no exerciseinduced effects on active GLP-1, PYY3-36, or overall appetite within and between groups.

Future directions
Future investigations should employ better study designs and begin to measure
these peripherally derived appetite peptides more frequently and over a longer period.
Recent reports have commented on the exact variability present in appetite-regulatory
responses (Goltz et al. 2018; Gonzalez et al. 2017; King et al. 2017) and as scientists it is
our duty to ensure our observations are not only valid but reproducible, as scientifically
sound conclusions should only be based off of such evidence. In order to properly
accomplish this, we ought to design better studies ensuring repeated exposures to the exact
same experimental conditions in cross-over designs thus allowing for the determination of
individual variability. Furthermore, studies into the effects of exercise on appetite should
make concerted efforts to measure (peptides and perceptions) more frequently and over a
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longer post-exercise period, thus enabling the observation of small changes that otherwise
would go undetected. It is quite possible that had we had better time point selection in the
current investigation, whether this be more frequent measurements (i.e., immediately post, 30-, 45-, 60-, 75-, 90-, etc.) and/or measurements over a longer period (i.e., >2.5 h postexercise), we might have observed greater magnitudes of change or small fluctuations in
response to exercise. Such decisions are made in the study design process and need to be
rationalized based on feasibility and funding, however, only by designing better studies to
answer our research questions will we truly advance the literature in this field.
Going forward there are many directions in which the exercise, appetite and obesity
literature could progress, however a great focus should be on gut microbiomes and
microbiota, the resident microorganisms in our intestines.

Behavioral traits are

transmissible via gut microbes as evidenced by experiments where mice raised germ-free
received intestinal content transplants and began to display the same behavioral phenotypes
as the donors (Bercik et al. 2011). While this is a novel concept yet to be translated into
humans, it makes logical sense that the brain could shape the microbial habitat of the gut
since the brain regulates gastrointestinal functions such as motility and nutrient absorption
(Rhee et al. 2009). Perhaps another way to interpret this evidence is to think of the brain
as a key mediator in the etiology of obesity. It could very well be the case that how the
brain imposes bacterial colonization of the gut leads to microbial dysregulation resulting
in obesity, or the gut becomes dysregulated because of obesity. Regardless, such gut
dysbiosis has recently been implicated as a key molecular mechanism stimulating innate
immune activity and thus leading to chronic systemic inflammation (Lam et al. 2017), such
as that present in obesity. Therefore, it would be interesting if future studies could
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transplant microbes from healthy lean donors (at rest and post-exercise) into obese hosts
and observe whether the transplants influence appetite-related parameters or even improve
their systemic state of inflammation. Moreover, obese rodents treated with antibiotics and
prebiotics have demonstrated an ability to reshape their gut microbiota and improve
metabolic function (Cani et al. 2008; Cani and Delzenne 2009), lending support to the idea
that the gut microbiota is dynamic and intricately linked to metabolic health. In light of
this, dairy feeding studies could be conducted in obese humans to examine the effects of
using microorganisms and prebiotics as a means of improving their gut dysbiosis and
potentially their appetite-regulatory profile.
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APPENDIX C.

REB # 5383

PARTICIPANTS NEEDED
• Are you a male between the ages of 18 and 30?
• Do you exercise less than or equal to 3x/week?
• Have you ever wondered how your appetite
changes in response to exercise?
If so you may be eligible to participate in a novel
research study examining how exercise influences
appetite. Participation involves 3 visits to the Energy
Metabolism Research Laboratory (~12.5 hours total)
where you will be fed breakfast and then asked to
cycle on a stationary bicycle. This study involves
taking blood from the forearm vein.
Compensation is $50.00

Email Greg McKie if interested
mcki1060@mylaurier.ca
122

PARTICIPANTS NEEDED
We are currently looking for participants to take part in a
research study investigating how appetite differs depending
on body type. Participants must be male, 18-30 years old,
and not exercising regularly. Participation involves 3 visits
to the Energy Metabolism Research Laboratory (~12.5 hours
total) at Wilfrid Laurier University where you will be fed
breakfast, asked to cycle on a stationary bicycle, and have
blood samples taken from your forearm veins. This project
has been approved by the WLU Research Ethics Board
(REB# 5383).
In appreciation for participation you will receive $50.00
If you satisfy the criteria below please email Greg McKie at:
mcki1060@mylaurier.ca
1. Measure your height in inches

2. Measure the circumference around your
waist in inches

3. If your waist circumference divided by
your height is greater than 0.50 you are
eligible to participate
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Do you fall within the orange area on the above chart?
If so you may be eligible to participate in a novel research study at
WLU (REB # 5383) investigating how appetite differs depending on
your body type. We are currently looking for 18-30 year old males
who do not exercise regularly. Participation involves 3 visits to
the Energy Metabolism Research Laboratory (~12.5 hours total)
where you will be fed breakfast and then asked to cycle on a
stationary bicycle. This study involves taking blood from the
forearm vein. Compensation is $50.00
Email Greg McKie if interested
mcki1060@mylaurier.ca
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Page 1 of 4

Subject’s Initials

ID#

Date

Time

AM
PM

PITTSBURGH SLEEP QUALITY INDEX
INSTRUCTIONS:
The following questions relate to your usual sleep habits during the past month only. Your answers
should indicate the most accurate reply for the majority of days and nights in the past month.
Please answer all questions.

1.

During the past month, what time have you usually gone to bed at night?
BED TIME ___________

2.

During the past month, how long (in minutes) has it usually taken you to fall asleep each night?
NUMBER OF MINUTES ___________

3.

During the past month, what time have you usually gotten up in the morning?
GETTING UP TIME ___________

4.

During the past month, how many hours of actual sleep did you get at night? (This may be
different than the number of hours you spent in bed.)
HOURS OF SLEEP PER NIGHT ___________

For each of the remaining questions, check the one best response. Please answer all questions.
5.

During the past month, how often have you had trouble sleeping because you . . .

a)

Cannot get to sleep within 30 minutes
Not during the
Less than
past month_____ once a week_____

b)

Three or more
times a week_____

Wake up in the middle of the night or early morning
Not during the
Less than
past month_____ once a week_____

c)

Once or twice
a week_____

Once or twice
a week_____

Three or more
times a week_____

Once or twice
a week_____

Three or more
times a week_____

Have to get up to use the bathroom
Not during the
Less than
past month_____ once a week_____
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APPENDIX G
LEAN

OBESE

20

Anxiety (mm)

Anxiety (mm)

10
0
-10
EX

-20

CTRL

-30

0
-10
EX
CTRL

-20
-30

Fasted

Pre-Ex

30

90

150

Fasted

0

2000

-2000

1500

Anxiety AUC

Anxiety AUC

10

-4000
-6000
-8000

CTRL

30

90

500
0

EX

CTRL

EX

OBESE

****

*

60

EX

60

CTRL

Fullness (mm)

Fullness (mm)

EX

40
20
0

CTRL

40
20
0
-20

-20
Fasted

Pre-Ex

30

90

Fasted

150

Pre-Ex

30

90

150

15000

10000
8000

Fullness AUC

Fullness AUC

150

1000

LEAN

80

Pre-Ex

6000
4000

10000

5000

2000
0

CTRL

EX

0

CTRL

EX
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LEAN

***

40

40

20
0
-20
-40

EX

20
0
-20
EX

-40

CTRL

-60

CTRL

-60
Fasted

Pre-Ex

30

90

150

Fasted

0

Pre-Ex
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-4000
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-10000

CTRL

-6000
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CTRL

EX
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30

*

0
-5
-10
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**
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0
-10
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-20

-20
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30
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0

Pre-Ex
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Nausea AUC

Nausea AUC
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Nausea (mm)

Nausea (mm)

5
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0

Hunger AUC

Hunger AUC
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0
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0
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0
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Prospective EI AUC

*
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Prospective EI (mm)
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Prospective EI (mm)
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10000

5000

0

CTRL
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APPENDIX H.
Correlations between blood analytes and overall appetite for the obese group
OVERALL APPETITE
Fasted

Pre-exercise

30 min postexercise

90 min postexercise

150 min
postexercise

IL-6
- CTRL
0.38
0.03
-0.01
-0.14
-0.49
- EX
-0.20
0.10
0.16
0.08
-0.53
GLP-1
- CTRL
0.20
0.49
0.93*
0.21
0.34
- EX
0.68
0.25
0.19
-0.44
-0.59
AG
- CTRL
-0.42
-0.02
-0.45
-0.07
-0.23
- EX
-0.13
0.00
-0.25
-0.35
-0.30
PYY
- CTRL
-0.45
-0.65
-0.48
-0.02
0.82*
- EX
0.12
-0.51
0.21
0.19
0.21
Note: Values are Pearson product-moment correlations (r). CTRL - control session;
EX - exercise session. * - P<0.05
Correlations between blood analytes and overall appetite for the lean group
OVERALL APPETITE
Fasted

Pre-exercise

30 min postexercise

90 min postexercise

150 min
postexercise

IL-6
- CTRL
0.01
-0.72
-0.65
0.12
0.02
- EX
-0.28
-0.20
-0.26
-0.33
0.43
GLP-1
- CTRL
0.03
-0.45
0.40
0.47
0.25
#
- EX
-0.19
-0.80
-0.03
-0.36
-0.53
AG
- CTRL
-0.56
0.72
0.97*
0.84*
0.24
*
- EX
0.60
0.83
0.31
0.69
0.11
PYY
- CTRL
0.38
-0.28
-0.50
-0.24
0.10
- EX
-0.03
-0.28
-0.72
-0.60
0.24
Note: Values are Pearson product-moment correlations (r). CTRL - control session;
EX - exercise session. * - P<0.05; # - P = 0.054
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